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Objective:  The purpose of this study is to fill the knowledge gap regarding 
nonmedical prescription stimulant use. The study has three aims: 1) to explore the 
temporal trends of prescriptions, nonmedical use, and Emergency Department (ED) 
visits for specific prescription stimulants; 2) to investigate the source of the misused 
stimulants and whether different sources correspond to different risk profiles; and 3) 
to identify subgroups among nonmedical prescription stimulant users by their 
concurrent problematic substance use in different age groups. 
Method: National surveys across 2006 to 2011 were used in all three aims. Aim 1 
used National Disease and Therapeutic Index (NDTI), National Survey on Drug Use 
and Health (NSDUH), and Drug Abuse Warning Network (DAWN) and ordinary 
linear square regression to assess the temporal trends in frequency of prescription, 
nonmedical use and ED visits involving Adderall and methylphenidate. Aim 2 used 
logistic regression models to compare the socio-demographic, mental health and 
behavioral problems and stimulant use-related problems according to source of 
nonmedically used stimulants using the NSDUH data. Aim 3 used latent class 
analysis to examine patterns of past-year problematic substance use in participants 
reporting past-year nonmedical prescription stimulant use in adult and adolescent 
participants in the NSDUH.  
Results: Analyses for Aim 1 revealed that temporal trends in treatment visits 
involving stimulants do not correspond to trends in nonmedical use and ED visits. 
Prescription visits for Adderall did not change over time, while nonmedical use and 
ED visits grew dramatically among adults. The major source of misused stimulants 
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was a physician for both Adderall and methylphenidates. Aim 2 showed that sources 
of misused stimulants were associated with onset, recency and severity of stimulant 
use, with illegal and physician sources both associated with earlier onset, greater 
odds of recent use and meeting the diagnostic criteria for stimulant use disorder. Aim 
3 identified a four-class model in both adults and adolescents including a Low 
substance class, a Prescription drug class, an Alcohol/Marijuana class, and a 
Multiple substance class. Individuals in the three classes other than the Low 
substance class were more likely to report psychological and social outcomes. 
Conclusions: The findings highlight the need to target drug diversion as a preventive 
strategy and a more nuanced preventive and treatment program that takes into 





DISSERTATION COMMITTEE MEMBERS 
Ramin Mojtabai, M.D., MPH, Ph.D. (Advisor) 
Eric C. Strain, M.D. (Chair) 
Rosa M. Crum, M.D., MPH 
Carla Storr, ScD, MPH 
DISSERTATION COMMITTEE MEMBER ALTERNATES 
Daniel Webster, Sc.D. 





There are, indeed, lots of people to thank. To my advisor, Dr. Ramin Mojtabai, thank 
you for your unconditional support, patient guidance, and the warmth and affection 
whenever I spent time with you. As William Arthur Ward used to say,” The 
mediocre teacher tells. The great teacher inspires.” You certainly inspire me to want 
to be a decent researcher, a tireless learner, and if possible, a generous mentor to my 
future advisees just by being who you are. To Drs. Rosa Crum, Silvia Martins, and 
Carla Storr, I have always enjoyed my time spent with you—You taught me how to 
think critically and express gently. Most importantly, you demonstrate how to be a 
female leader in the competitive academia, which has shaped me gradually. To Dr. 
Eric Strain, as I met you in Taiwan 5 years ago as a psychiatric resident, I had never 
have dreamt of working with you. Thank you for always being supportive, through 
emails or in person. Working with you has been even better than what I had dreamt 
of. I would like to thank Dr. Willaim Eaton for believing in my potential and Mrs. 
Patty Scott for being the gentle babysitter for each one of us in this program. Also, I 
could not be as focused as I was without the generous support from Sommer 
Scholarship. To my dear parents and family, if I have shown any resilience and 
strength along the way, that comes from you— your love has given me enormous 
sense of security and self-confidence that no one could take away. To the love of my 
life, Hao, thanks for being my Doraemon, the father of my daughter, and my best 
friend who knows me so well and continues to do so. To Nora, thank you for 




accepted, valued this time in my life and I thank everyone who has been a part of this 

















































TABLE OF CONTENTS 
ABSTRACT .................................................................................................................. i 
DISSERTATION COMMITTEE ................................................................................ ii 
ACKOWLEDGEMENTS ........................................................................................... iv 
LIST OF CONTENTS ............................................................................................... vii 
LIST OF TABLES ....................................................................................................... x 
LIST OF FIGURES ................................................................................................... xii 
CHAPTER 1. INTRODUCTION ................................................................................ 1 
1.1. Problem statement .............................................................................................. 1 
1.1.1.Trends of prescription of prescription stimulants ..................................... 2 
1.1.2.Trends in nonmedical use of prescription stimulants ............................... 3 
1.1.3.Sources of prescription stimulants ............................................................ 4 
1.1.4.Profiles of nonmedical prescription stimulant users................................. 4 
1.2. Study aims .......................................................................................................... 6 
1.3. Chapter overview ............................................................................................... 8 
CHAPTER 2. PRESCRIPTIONS, NONMEDICAL USE, AND EMERGENCY 
DEPARTMENT VISITS INVOLVING ADHD STIMULANTS ............................. 10 
2.1. Introduction ...................................................................................................... 12 
2.2. Methods ............................................................................................................ 14 
2.3. Results .............................................................................................................. 18 
2.4. Discussion ........................................................................................................ 21 




CHAPTER 3. SOURCES OF NONMEDICALLY USED PRESCRIPTION 
STIMULANTS: DIFFERENCES IN RECENCY AND SEVERITY OF MISUSE IN 
A 
POPULATION-BASED STUDY .............................................................................. 32 
3.1. Introduction ...................................................................................................... 34 
3.2. Methods ............................................................................................................ 35 
3.3. Results .............................................................................................................. 40 
3.4. Discussion ........................................................................................................ 42 
3.5. Conclusion ....................................................................................................... 45 
CHAPTER 4. PATTERNS OF CONCURRENT PROBLEMATIC SUBSTANCE 
USE AMONG NONMEDICAL ADHD STIMULANT USERS .............................. 50 
PART A. ADOLESCENT 
4.1. Introduction ...................................................................................................... 51 
4.2. Methods ............................................................................................................ 53 
4.3. Results .............................................................................................................. 55 
4.4. Discussion ........................................................................................................ 59 
4.5. Conclusion ....................................................................................................... 62 
PART B. ADULT 
4.1. Introduction ...................................................................................................... 73 
4.2. Methods ............................................................................................................ 75 
4.3. Results .............................................................................................................. 80 
4.4. Discussion ........................................................................................................ 84 
4.5. Conclusion ....................................................................................................... 87 
ix 
 
CHAPTER 5. DISCUSSION ..................................................................................... 96 
5.1. Overview of findings ....................................................................................... 96 
5.2. Study limitations .............................................................................................. 99 
5.3. Study Strengths .............................................................................................. 101 
5.4. Public health implications .............................................................................. 102 
5.5. Future directions ............................................................................................ 103 
5.6. Conclusion ..................................................................................................... 105 
APPENDICES ......................................................................................................... 106 
REFERENCES ......................................................................................................... 109 
















LIST OF TABLES 
CHAPTER 2.  
Table 1. Characteristics of participants in samples examining trends in prescriptions, 
nonmedical use and emergency department visits involving Adderall and 
methylphenidate .......................................................................................................... 26 
Table 2. Reasons for past-year emergency department visits involving Adderall or 
methylphenidate .......................................................................................................... 28 
Table 3. Sources of stimulants for past-month nonmedical use of Adderall and 
methylphenidate .......................................................................................................... 30 
CHAPTER 3.  
Table 1. Different types of prescription stimulant sources of past-year nonmedical 
prescription stimulant users ........................................................................................ 47 
Table 2. Characteristics of past-year nonmedical ADHD stimulant based on source of 
misused stimulants in a sample of the US population aged 12 and above .................. 48 
Table 3. Onset, recency and severity of past-year nonmedical ADHD stimulant use 
based on source of misused stimulants in a sample of the US population aged ......... 50 
CHAPTER 4.  
Part A: 
Table 1. Characteristics of past-year nonmedical ADHD stimulant users in a sample 
of the US adolescents aged 12-17 ............................................................................... 66 
Table 2. Characteristics of past-year nonmedical ADHD stimulant users, by 
concurrent problematic substance use class in a sample of the US population aged 
12-17 ........................................................................................................................... 67 
xi 
 
Table 3. Comparison of classes of past-year nonmedical ADHD stimulant users 
identified through latent class analysis in a sample of the US population aged 12-
17 ................................................................................................................................. 68 
Part B: 
Table 1. Characteristics of past-year nonmedical ADHD stimulant users in a sample 
of the US population aged 18 and above .................................................................... 89 
Table 2. Characteristics of past-year nonmedical ADHD stimulant classes identified 
through latent class analysis in a sample of the US population aged 18 and above ... 91 
Table 3. Comparison of classes of past-year nonmedical ADHD stimulant users 
identified through latent class analysis in a sample of the US population aged 18 and 















LIST OF FIGURES 
CHAPTER 2.  
Figure 1A. Temporal trends in prescription, nonmedical use, and ED visits involving 
Adderall and methylphenidate among adolescents (12-17 years) .............................. 30 
Figure 1B. Temporal trends in prescription, nonmedical use, and ED visits involving 
Adderall and methylphenidate among adults (18 years old or above) ....................... 31 
CHAPTER 4.  
Part A: 
Figure 1. Conditional probabilities of problematic use of substances among 2,203 
adolescents of 2006–2011 National Survey on Drug Use and Health with past-year 
nonmedical ADHD stimulant use categorized using latent class analysis .................. 70 
Part B: 
Figure 1. Conditional probabilities of problematic use of substances among 6,103 
adults  
of 2006–2011 National Survey on Drug Use and Health with past-year nonmedical 









Chapter 1: Introduction 
1.1. Problem statement 
Nonmedical use of prescription drugs ranks as the second most common class 
of illicit drug use in the United States, with an annual average of 15.7 million people 
aged 12 or older having used prescription drugs nonmedically between 2005 and 
2011 (SAMHSA, 2012). Nonmedical use can be defined as use without a doctor’s 
prescription, use in greater amount or for a longer period than prescribed, or use for 
reasons other than the doctor’s recommendation (Blanco et al., 2007). Among the 
prescription drugs, prescription stimulants have been commonly used nonmedically 
especially among young adults and adolescents (NIDA, 2009). 
Prescription stimulants mainly refer to stimulants prescribed for treatment of 
a variety of medical conditions, including narcolepsy, obesity, and mainly attention-
deficit/hyperactivity disorder (ADHD) (Greenhill et al., 2002). Methylphenidate 
(Ritalin), dextroamphetamine (Dexedrine) and mixed-salts amphetamine (Adderall), 
considered as first-line pharmacotherapy for the treatment of ADHD, are sold in 
different brand names. There is increasing public concern and research interest 
regarding the growing nonmedical use of these ADHD stimulants in the past decades 
(Arria et al., 2008; McCabe et al., 2007a; McCabe et al., 2005; Teter et al., 2005; 
Teter et al., 2006). In 2011, 1.1 million Americans aged 12 or older used prescription 
stimulants nonmedically in the past year (SAMHSA, 2012).  
There are several adverse physical, psychological and social consequences 
related to nonmedical use of prescription stimulants. First, the abuse potential of 
these stimulants has long been recognized, resulting in their classification as schedule 
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II substances in the Controlled Substances Act (CSA) (Drug Enforcement 
Administration, 2003). Both Adderall and methylphenidate work on dopamine 
system, which is involved with the addiction reward pathway (Pliszka et al., 1996). 
Second, there are reports regarding the increased cardiovascular risks associated with 
the use of these stimulants (Gould et al., 2009; Sichilima and Rieder, 2009; Westover 
and Halm, 2012), leading the US Food and Drug Administration (FDA) to put a 
black box warning on Adderall (FDA, 2006). Third, the use of these ADHD 
stimulants may increase risks of psychosis or mood disorder (Chakraborty and 
Grover, 2011a; Mosholder et al., 2009). The health and social burden of the increased 
nonmedical use of stimulants is reflected in the  increase in Emergency Department 
(ED) visits involving ADHD stimulants between 2005 and 2010 (SAMHSA, 2013a). 
1.1.1. Trends of prescription of prescription stimulants  
The legal production of methylphenidate (Ritalin) and amphetamine 
(Adderall, Dexedrine) in the U.S. has grown remarkably since 1990 (Safer et al., 
1996; White et al., 2006). The rate of their distribution is carefully monitored by the 
Drug Enforcement Administration (DEA), which establishes quotas for schedule II 
controlled substances by analyzing past sales, inventory, anticipated need, and 
market trend data. The growing demand for prescription stimulants in the U.S. is 
evidenced by the fact that the methylphenidate quota increased from 1,768 kilograms 
in 1990 to 96,750 kilograms in 2013, and the amphetamine quota increased from 417 
to 49,000 ( Drug Enforcement Administration, 2013). The rise in prescription and 
consumption of these medicines could be attributed to several factors, including an 
increased  diagnosis of ADHD (Olfson et al., 2003; Safer, 2000; Safer et al., 1996; 
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Zito et al., 2003) and increased duration of treatments (Safer, 2000), and possibly 
increased misuse rates of these medications.  
The increased availability of ADHD stimulants have long been suspected to 
be associated with increased nonmedical use of these drugs (Cohen et al., 2006; 
McCabe and Boyd, 2005), evidenced by numerous college based and national studies 
showing remarkable increase of nonmedical use (Arria et al., 2008; McCabe et al., 
2005; SAMHSA, 2009a; Teter et al., 2006). However, there is so far no study 
examining the relationship of temporal trends in prescriptions and nonmedical use of 
ADHD stimulants.     
1.1.2. Trends in nonmedical use of prescription stimulants 
Abundant evidence has shown that nonmedical use of prescription stimulants 
mainly affect young individuals (Johnston, 2003a-b; McCabe et al., 2004; SAMSHA, 
2008b), especially college students (McCabe et al., 2005; SAMHSA, 2009a; White et 
al., 2006). In college-based studies the lifetime prevalence of prescription stimulant 
misuse and abuse has ranged from 3% to 16% (Babcock and Byrne, 2000; Hall et al., 
2005; Teter et al., 2003). The misuse of these medications is not limited to college 
age youth. Between 3.3% to 4.5% of middle school and high school youth also report 
nonmedical use of prescription stimulants (McCabe and Teter, 2007; McCabe et al., 
2004).  
Limited data exist regarding the trends in nonmedical use of specific 
stimulants. Past research mainly combined all prescription stimulants together 
(McCabe et al., 2005; SAMHSA, 2009a; White et al., 2006) or focused on one 
specific prescription stimulant, most often methylphenidates (Babcock and Byrne, 
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2000; Safer et al., 1996; Teter et al., 2003). To the best of our knowledge, only one 
study has examined the trend of nonmedical use of different prescription stimulants, 
in which nonmedical use of Adderall proved to be more prevalent than nonmedical 
use of methylphenidates among college students (Teter et al., 2006). Thus, there is a 
need for more information on trends in nonmedical use of specific stimulants, and the 
association of such use with the trend of prescription or adverse consequences of 
these drugs.  
1.1.3. Sources of prescription stimulants 
A large number of studies have examined the characteristics and correlates of 
nonmedical prescription stimulant use; however, few studies have examined the 
sources of misused stimulants. Most of these studies identified a friend or relative as 
the major source for misused prescription stimulants (DeSantis and Hane, 2010; 
Garnier-Dykstra et al., 2012; McCabe et al., 2006b; White et al., 2006). A recent 
study revealed that 89% of college students reported obtaining the misused 
stimulants from a friend or significant other (DeSantis and Hane, 2010). In addition, 
the high availability of stimulants over the Internet has been documented by a 
previous study and has been suspected to be an increasing source of prescription 
drugs (Schepis et al., 2008) However, overall, Internet remains a minor source of 
nonmedically used stimulants (Inciardi et al., 2010). Examining how sources vary 
across the socio-demographic spectrum would provide useful information for design 
of preventive interventions and even individual treatment planning. For example, 
knowing whether use of a specific source might signal a greater likelihood of other 
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substances use, persistence of stimulant use problem may be a useful guide for 
treatment planning.  
1.1.4. Profiles of nonmedical prescription stimulants users 
 As discussed above, nonmedical use of prescription stimulants mainly affects 
young adults and adolescents (Arria et al., 2008; Kroutil et al., 2006; McCabe et al., 
2007a; McCabe et al., 2005; McCabe and Teter, 2007; SAMHSA, 2009a; Teter et al., 
2005; Teter et al., 2006). In national surveys such as Monitoring the Future (MTF) 
and the National Survey on Drug Use and Health (NSDUH), college students were 
found to be twice as likely to report nonmedical use of prescription stimulants than 
their counterparts not attending college (Johnston, 2003; SAMHSA, 2009a). College 
students who reported nonmedical prescription stimulant use were also more likely to 
be male, white, members of fraternities and sororities, and to have earned lower 
grade point averages (Arria et al., 2008; McCabe et al., 2005; Teter et al., 2005; Teter 
et al., 2006). However, no sex difference was found in adolescent users (Herman-
Stahl et al., 2007; McCabe et al., 2004). Regardless of age, nonmedical users of 
prescription stimulants were more likely to report use of alcohol, cigarettes, 
marijuana, ecstasy, cocaine and deviant behaviors (Arria, 2008; Herman-Stahl et al., 
2006, 2007; McCabe et al., 2006a; McCabe et al., 2004, 2006b; SAMHSA, 2009a; 
Teter et al., 2005; Teter et al., 2006). The reasons for using stimulants nonmedically 
included improving attention, partying, reducing hyperactivity, and improving grades 
(Garnier-Dykstra et al., 2012; McCabe et al., 2004; Teter et al., 2005; Teter et al., 
2006; White et al., 2006). 
6 
 
The variations in the social and health consequences of stimulant misuse, 
concomitant use of other substances and the different motives reported by youth who 
use these drugs nonmedically suggests that these users are not a homogenous group. 
However, little is known about possible subgroups among these youth as most past 
research has compared nonmedical prescription stimulant users to non-users 
regarding their other substance use and risky behaviors (McCabe et al., 2007a; 
McCabe et al., 2005; McCabe and Teter, 2007; SAMHSA, 2009a; Teter et al., 2005; 
Teter et al., 2006; White et al., 2006). A better understanding of this heterogeneity 
may enhance understanding of the epidemiology of nonmedical use of stimulants and 
contribute to prevention and treatment efforts. It is conceivable that some youth 
misuse stimulants as study aids or to self-medicate their attention problems; whereas, 
others may be using these drugs recreationally along with alcohol or other illegal 
drugs. These groups would be expected to have different substance use profiles as 
well as different health, social and academic outcomes.  
  
1.2. Study aims 
Previous studies have shown an increasing trend in stimulant prescriptions 
and in nonmedical use of these prescription stimulants; however, the role of 
prescription (i.e. availability of these drugs) in nonmedical use is rarely examined. 
The 2006 FDA black box warning on Adderall makes examination of these trends 
especially timely. To address this question, the first aim of this project was to 
examine the recent trends in prescription and nonmedical use of two commonly 
prescribed and misused stimulants: methylphenidate and Adderrall. More specifically 
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we examined quarterly trends in prescriptions, nonmedical use, and ED visits 
associated with these drugs in adults and adolescents.  
Second, we capitalized on the wide variations of sources of stimulants to 
better characterize the profiles of nonmedical prescription stimulant users. In 
addition, we further examined the relationship between the sources of these 
stimulants and the onset, recency, and severity of stimulant use problems. This 
analysis sheds light on the role of source as an indicator of seriousness and 
persistence of stimulant misuse and varied treatment needs of individual stimulant 
users based on their source of stimulants.  
Lastly, whether there exist heterogeneous subgroups among stimulant users 
with regard to their concurrent substance use patterns is examined as the third aim of 
this study. We will further examine the socio-demographic characteristics, mental 
health and behavioral of subgroups of participants thus identified. 
The study has the following specific aims and hypotheses: 
 Aim 1:  To assess the association between three national trends from 2006-
2011: treatment visits involving stimulants using the National Disease and 
Therapeutic Index (NDTI) data, nonmedical use based on the National Survey on 
Drug Use and Health (NSDUH) data, and emergency department (ED) visits using 
Drug Abuse Warning Network (DAWN) data. Analyses will be conducted separately 
for methylphenidate and Adderall and for adults and adolescents. 
Hypothesis 1: The increasing trends in the prescription of specific stimulants 
will be associated with the increased nonmedical use of the same prescription 
stimulants, which will be associated with increased ED visits. 
8 
 
Aim 2: To investigate whether different sources of misused stimulants are 
associated with different socio-demographic, psychological and behavioral profiles 
and stimulant use problems using 2006-2011 NSDUH data.  
Hypothesis 2: Individuals who report obtaining their stimulants from illegal 
sources will have distinct socio-demographic, psychological and behavioral profiles 
and are more likely in engage in other illegal behavior compared to other sources.  
Aim 3: To explore subgroups of individuals who use prescription stimulants 
nonmedically according to concurrent drug use profiles using latent class analysis 
and to identify socio-demographic, mental health and behavior correlates of these 
subgroups using the NSDUH data. 
Hypothesis 3: Nonmedical stimulant users are comprised of at least two 
classes of participants: one class with a greater prevalence of concurrent problematic 
substance use and maladaptive behaviors, and another with lower prevalence of 
concurrent substance use and associated problems.   
 
1.3.Overview of chapters 
1.3.1. Chapter 2  
Chapter 2 aims to investigate recent temporal trends in prescriptions, 
nonmedical use, and Emergency Department (ED) visits of two most commonly 
prescribed stimulant medications (Adderall and methylphenidate) using three 
representative national surveys conducted between 2006-2011: National Disease and 
Therapeutic Index (NDTI), a survey of office-based practices, National Survey on 
Drug Use and Health (NSDUH), a population survey of substance use, and Drug 
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Abuse Warning Network (DAWN), a survey of ED visits. The associations of the 
three trends among adults and adolescents are examined using Ordinary linear square 
(OLS) regression. 
1.3.2. Chapter 3  
Chapter 3 aims to investigate the relationship between sources of misused 
stimulants and socio-demographic, psychological and behavioral profiles of 
nonmedical prescription stimulant users, and onset, recency and severity of stimulant 
use problems using the 2006-2011 NSDUH data. Multinomial logistic regression was 
used to examine these associations using both unadjusted and adjusted regression 
models.  
1.3.3. Chapter 4  
Chapter 4 addresses Aim 3 using data on NSDUH adult and adolescent 
participants who reported past-year nonmedical use of ADHD stimulants. We used 
latent class analysis (LCA) to examine patterns of past-year problematic substance 
use (met any criteria for abuse or dependence). Multivariate latent regression was 
used to assess the association of socio-demographic, mental health and deviant 
behavior characteristics with the latent classes.  
1.3.4. Chapter 5  
Chapter 5 summarizes the main findings from each study aim (i.e., Chapters 
2-4), describes study limitations and strengths, and discusses the public health 




Chapter 2: Prescriptions, Nonmedical Use, and Emergency Department Visits 
Involving ADHD Stimulants 
Abstract 
Importance: There are growing concerns about the nonmedical use of stimulants 
medications. However, little is known regarding the temporal trends in prescription, 
nonmedical use and emergency department (ED) visits involving these medications 
in the United States.   
Objectives: To investigate recent trends in prescriptions, nonmedical use of, and ED 
visits for Adderall (dextroamphetamine-amphetamine) and methylphenidate, two 
commonly prescribed stimulant medications, in adults and adolescents.   
Design, Setting, and Participants: We used data from three representative national 
surveys conducted between 2006-2011: National Disease and Therapeutic Index 
(NDTI), a survey of office-based practices, National Survey on Drug Use and Health 
(NSDUH), a population survey of substance use, and Drug Abuse Warning Network 
(DAWN), a survey of ED visits.  
Main Outcomes and Measures: Quarterly treatment visits (NDTI), nonmedical use 
(NSDUH), and ED visits (DAWN); source of misused stimulants (NSDUH), and 
reasons for ED visits (DAWN). 
Results: In adolescents, prescriptions of Adderall and methylphenidate decreased 
over time; nonmedical use of Adderall remained stable and nonmedical use of 
methylphenidate declined for 54.4% in 6 years. ED visits involving either medication 
remained stable among adolescents. In adults, prescription visits for Adderall did not 
change over time, while nonmedical use went up by 67% and ED visits went up by 
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156% and were strongly associated. Prescriptions, nonmedical use, and ED visits 
involving methylphenidate did not change in adults. For both drugs, the major source 
across age groups was a friend or relative. In two-thirds of the cases, the friend or 
relative had obtained the medication through prescriptions from a physician.   
Conclusions: Trends over time in the number of prescriptions for stimulants do not 
correspond to trends in reports of nonmedical use and ED visits. Increases in 
problems related to stimulant misuse may not relate simply to temporal prescribing 
trends. Physician prescriptions were the major source of nonmedical stimulant drug 
use, suggesting that prevention strategies should target drug diversion routes as well 




The abuse potential of  prescription stimulants, commonly used for treatment 
of attention deficit/hyperactivity disorder (ADHD), has long been recognized, 
resulting in classification of these drugs as schedule II substances in the Controlled 
Substances Act (CSA) (Drug Enforcement Administration, 2003). Nonmedical use of 
these medications has increased in recent years (Arria et al., 2008; McCabe et al., 
2007a; McCabe et al., 2005; Teter et al., 2005; Teter et al., 2006) and student 
population is especially vulnerable to the problem. In national surveys such as 
Monitoring the Future (MTF) and the National Survey on Drug Use and Health 
(NSDUH), college students were twice more likely to report nonmedical use of 
prescription stimulants than their counterparts not attending college (Johnston, 
2003a-a; SAMHSA, 2009a). In another study among middle and high school 
students, 4.5% reported nonmedical stimulant use, of whom, 23.3% reported being 
approached to sell, give, or trade these drugs (McCabe et al., 2004). The potential 
consequences of nonmedical use included other substance use, psychiatric 
comorbidities, criminal involvement, cardiovascular conditions and other adverse 
health outcomes among individuals using stimulants (Arria et al., 2008; Gould et al., 
2009; Higashi et al., 2011; McCabe et al., 2005; NIDA, 2009b; Sichilima and Rieder, 
2009).  
The US Food and Drug Administration (FDA) put a black box warning on 
Adderall in 2006 due to its associated cardiovascular risks (Food and Drug 
Administration, 2006). There is some evidence that Adderall prescriptions declined 
after the FDA warning. In one study, treatment visits for Adderall declined from 36% 
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in 2004 to 24% in 2008 (Kornfield et al., 2013). Nevertheless, Emergency 
Department (ED) visits involving ADHD medications tripled from 2005 to 2010 
(SAMHSA, 2013a). Similarly, in another study based on the Poison Control Center's 
National Poison Data System, calls related to ADHD medication misuse in teenagers 
rose by 76%, much faster than calls for other substances abused by adolescents 
(Setlik et al., 2009).   
Furthermore, prescription trends and trends in nonmedical use may reflect 
different population groups. Although the majority of ADHD medications are 
prescribed for children and adolescents, most of the nonmedical ADHD stimulant 
users are young adults (Arria et al., 2008; McCabe et al., 2005; McCabe et al., 2007c; 
Teter et al., 2005; Teter et al., 2006; White et al., 2006). Also, ED visits for 
nonmedical use of ADHD stimulants have showed distinct patterns for adolescents 
and adults (SAMHSA, 2013a). Trends in prescription, nonmedical use, and ED visits 
for specific ADHD stimulants have rarely been examined separately for adults and 
adolescents. An improved understanding of nonmedical use of ADHD stimulants in 
these two populations would be a valuable step in the development of effective 
prevention and treatment interventions. 
This study aimed to elucidate these trends and their relationships by 
examining temporal trends in prescriptions, nonmedical use, and ED visits involving 
Adderall and methylphenidate among adults and adolescents between 2006 and 2011. 
We assessed the associations of these trends using three nationally representative 
datasets: National Disease and Therapeutic Index (NDTI), a survey of office-based 
practices, National Survey on Drug Use and Health (NSDUH), a population survey 
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of substance use, and Drug Abuse Warning Network (DAWN), a survey of 
emergency department (ED) visits. Additionally, we examined the reported sources 
of nonmedically used Adderall and methylphenidates, and the reasons for ED visits 
involving these medications.   
 
2. Method 
2.1. Samples  
Data on prescription frequency were obtained from NDTI, a nationally 
representative audit of office-based physicians conducted by IMS Health. The NDTI 
uses a two-stage sampling procedure and collects data on patient contacts from 
approximately 4,300 physicians randomly selected within strata defined by specialty 
and geographic area, generating approximately 350,000 annual contact records. We 
limited our analyses to the approximately 85% of contacts generated through office 
visits. Our primary unit of analysis was a visit during which Adderall or 
methylphenidate was prescribed or continued—referenced to below as a treatment 
visit. There were 26,469 contacts involving ADHD medications for patients aged 12 
years and older, including 18,143 for Adderall and 8,654 for methylphenidate.  
Data on nonmedical use of medications was obtained from NSDUH public 
use data for 2006 to 2011 (N=338,495). The NSDUH is an annual cross-sectional 
survey sponsored by the Substance Abuse and Mental Health Services 
Administration (SAMHSA) and is designed to provide estimates of the prevalence of 
alcohol and drug use in the household population of the United States, 12 years of 
age and older. The survey employs an independent multistage area probability 
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sample for each of the 50 states and the District of Columbia. The response rate for 
household screening ranged from 87% to 91% and for completed participant 
interviews from 74% to 76% across the 6 years. Detailed information about the 
sampling and survey methodology of NSDUH are found elsewhere (SAMHSA, 
2007, 2008, 2009, 2010, 2011, 2012). Among the NSDUH 2006–2011 participants, 
there were 7,151 nonmedical Adderall users and 3,197 nonmedical methylphenidate 
users. 
Data on ED visits involving Adderall and methylphenidate were obtained 
from DAWN for 2006 to 2011 (N= 1,648,992). DAWN is sponsored by the 
SAMHSA, and consists of a network of over 250 hospitals that monitors drug-related 
visits to hospital EDs. The DAWN data are collected directly from the medical 
records of patients treated in the EDs and the reports are submitted electronically 
using the Electronic Hospital Emergency Reporting System (eHERS), a customized 
system developed specifically for DAWN. Detailed information about the sampling 
and survey methodology of DAWN can be found elsewhere (SAMHSA, 2011). 
Between 2006 and 2011, a total of 9,181 visits involved Adderall and 2,483 involved 
methylphenidate.  
2.2. Assessments 
Prescription frequency in NDTI was assessed by a physician visit during 
which ADHD stimulants were prescribed or continued. We focused on two groups of 
medications: Adderall (including Adderall and Adderall XR) and methylphenidates 
(including Ritalin, Ritalin SR, Ritalin LA, Concerta, Methylin, Methylin ER, 
Metadate). NDTI links each drug therapy to a specific six-digit taxonomic code 
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capturing diagnostic information similar to the International Classification of 
Diseases 9th Revision (ICD-9).  
Nonmedical use of methylphenidate in NSDUH was assessed using the 
following question: “Have you ever, even once, used Ritalin or Methylphenidate that 
was not prescribed for you or that you took only for the experience or feeling it 
caused?” A similar question was asked regarding the nonmedical use of Adderall. 
Each question was followed by a question about the time of the most recent use. We 
defined past-year nonmedical ADHD stimulant use by a positive response to the 
questions and further indicated that the last use was within 12 months. 
 NSDUH participants who reported using ADHD stimulants nonmedically in 
the past 30 days were asked a series of questions on how they had obtained these 
drugs. The sources ascertained included friends/relatives (got for free, bought from 
them or took without asking), direct physician source (got from one doctor or doctor 
shopping), illegal source (buying from a drug dealer or via internet), other source 
(fake prescriptions or some other way), and multiple sources (have more than two of 
the above-mentioned sources). We combined the source variables into five larger 
categories as some of the specific sources were endorsed by very few participants. 
Participants who reported obtaining the stimulant from a friend or relative for free 
were asked how that friend or relative had obtained the drug (secondary source). 
Those who reported either primarily or secondarily from a physician were recorded 
as having obtained the drug from a physician source. 
 Information on ED visits in DAWN included medication or substances of 
abuse that might contribute to the visit based on the medical record. We focused on 
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ED visits involving methylphenidate or Adderall. DAWN also assessed the reasons 
for the ED visits. We categorized the reasons for ED visits into three categories based 
on a previous study (Olfson et al., 2003): nonmedical use (including suicide attempt, 
overmedication, accidental ingestion and malicious poisoning), adverse reaction, and 
others.  
2.3. Statistical analyses 
 We restricted the samples from all three datasets to participants aged 12 years 
and older in order to have consistent age ranges for the three data sources. Physician 
visits, nonmedical use and ED visits involving methylphenidate and Adderall were 
examined quarterly from 2006 to 2011 separately for adults (aged 18 or above) and 
teenagers (aged 12-17). Ordinary linear square (OLS) regression was used to assess 
the temporal trend in frequency of prescription, nonmedical use and ED visits across 
quarters. Time was the independent variable of interest in these models. The 
associations between prescription frequency and nonmedical use and between 
nonmedical use and ED visits were also examined using OLS regression. We tested 
OLS models for autocorrelation across time using Durbin-Watson tests (Durbin and 
Watson, 1950) and we further reported results adjusting for autocorrelations using 
Newey-West standard errors if the Durbin-Watson test for autocorrelation produced 
inconclusive results. 
Next, we examined the distribution in sources of methylphenidate and 
Adderall used in the past 30 days including primary and secondary sources across 
different age. In order to examine whether time modifies the relationship between 
nonmedical ADHD stimulant use and source of the misused drug, we divided these 
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users into three mutually exclusive groups: 1) nonmedical Adderall users only, 2) 
nonmedical methylphenidate users only and 3) nonmedical Adderall and 
methylphenidate users (as a large proportion of participants reported using both 
drugs). Reasons for ER visits were analyzed separately for Adderall and 
methylphenidate among adolescents (age 12-17) and adults (aged 18 and above). 
 To obtain nationally representative quarterly frequency estimates, data were 
weighted to reflect the complex design of the NSDUH and DAWN samples and were 
analyzed by Stata 13.0 software (StataCorp, 2013). We used Taylor series estimation 
methods as implemented in STATA svy commands to obtain proper standard error 
estimates for the cross-tabulations and logistic regressions.  
 
3. Results 
3.1. Demographics characteristics 
The demographic characteristics of individuals included in the three samples 
are presented in Table 1. Based on the NDTI data, individuals who were prescribed 
ADHD stimulants were more likely to be male than female (Adderall: 58.5%, 
methylphenidate: 53.7%), non-Hispanic whites (Adderall: 85.4%, methylphenidate: 
87.0%), and most commonly in the 12-17 years age range (Adderall: 43.0%, 
methylphenidate: 30.9%). Notably, while 26% of methylphenidate visits included 
adults age 50 years and older, only 8.1% of Adderall visits fell in this age range.  
Based upon the NSDUH data, past-year nonmedical users of both Adderall 
and methylphenidate were more likely to be male (Adderall: 55.6%, 
methylphenidate: 53.7%), aged 18-25 years (Adderall: 59.7%, methylphenidate: 
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50.8%), and white (Adderall: 86.4%, methylphenidate: 86.8%; Table 1). The 
proportion of nonmedical Adderall users of all users increased from 13.3% in 2006 to 
20.2% in 2011, while the proportion of nonmedical methylphenidate users in each 
year remained relatively stable. 
ED visits resulting from Adderall use, as reported in DAWN (Table 1) were 
more frequent among females (54.9%), those aged 35-54 years (26.4%), and whites 
(86.8%). ED visits involving methylphenidate use were equally common in both 
sexes (50.0%), more frequent in those aged 12-17 years (26.8%), and in whites 
(91.1%). There was an increasing trend over 6 years for ED visits involving Adderall 
and methylphenidate use. 
3.2. Temporal trends among adolescents  
Adderall treatment visits among adolescents decreased from 479,000 in the 
first quarter of 2006 to 223,000 visits in the last quarter of 2011. Since Adderall visits 
in adolescents showed inconclusive results, we adjusted this model for autoregression 
(regression coefficient [B]= -9.24, standard error [SE]=1.57, p<0.001) (Figure 1A). 
Nonmedical Adderall use and ED visits, however, did not change appreciably during 
this period. Methylphenidate treatment visits in adolescents also decreased from 
191,000 in the first quarter of 2006 to 113,000 visits in the last quarter of 2011 (B=-
3.47, SE=0.68, p<0.001). Nonmedical use of methylphenidate decreased significantly 
in this period from 2.06% in the first quarter of 2006 to 0.94% in the last quarter of 
2011 (B=-0.04, SE=0.01, p<0.001). The prevalence of ED visits involving 
methylphenidate for adolescents did not show a significant change over time (Figure 
1A). There was a statistically significant association between methylphenidate visits 
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and nonmedical use of methylphenidate (B=0.01, SE=0.002, p=0.001), other 
associations between the temporal trends were all non-significant (Appendix Table 
1). 
3.3. Temporal trends among adults  
Adderall treatment visits among adults changed little in the study period, 
from 379,000 in the first quarter of 2006 to 364,000 visits in the last quarter of 2011 
(Figure 1B). However, the prevalence of past-year nonmedical use of Adderall in 
adults increased over the study period, from 0.73% in the first quarter of 2006 to 
1.22% in the last quarter of 2011 (B=0.10, SE=0.01, p<0.001). ED visits involving 
Adderall in adults similarly increased from 0.34% in the first quarter of 2006 to 
0.87% in the last quarter of 2011 (B=0.02, SE=0.003, p<0.001) (Figure 1B). 
Furthermore, there was a statistically significant association between nonmedical 
Adderall use and ED visits involving Adderall in this age group over the study period 
(B=0.68, SE=0.13, p <0.001). Physician visits, nonmedical use and ED visits 
involving methylphenidate did not change appreciably during the study period 
(Appendix Table 1).   
3.4. Sources of nonmedically used stimulants  
Friends or relatives were the major primary source of nonmedically used 
stimulants, regardless of age groups and medication type, contributing 59.9% to 
68.5% of all sources of nonmedically used stimulants (Table 2). In addition, we 
found a physician’s prescription comprised almost two-thirds of secondary drug 
source for both drugs across age groups, ranging from 59.3% to 75.4%. We then 
created three mutually exclusive groups of nonmedical ADHD stimulant users in 
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order to examine the effect modification of time. The analyses showed that 
participants who used both Adderall and methylphenidate nonmedically were more 
likely to obtain the drug from physician sources, regardless of whether this was the 
primary or secondary source (OR=1.57, 95% CI=1.11, 2.21, P=0.009), compared to 
those only using Adderall alone. There was no evidence of an effect modification 
over the study period (P=0.087), indicating that the sources of misused drugs did not 
change appreciably across time. 
3.5. Reasons for ED visits 
ED visits due to nonmedical use of Adderall or methylphenidate among 
adults constituted more than one-third of all drug-related ED visits (Adderall: 30.3%, 
methylphenidate: 35.9%) (Table 3). In addition, for adolescents, 46.2% of ED visits 
involved nonmedical use of Adderall, and 37.3% involved methylphenidate. It is 
noteworthy that adverse reactions due to medical use of methylphenidate constituted 
about half of the ED visits among adolescents.  
 
4. Discussion 
 This study had three principal findings. First, prescription visits did not 
necessarily show coincident changes with prevalence of nonmedical use. For 
instance, the prevalence of nonmedical use of Adderall in adults increased 
remarkably while prescription trends of this drug remained stable. Second, 
nonmedical use of Adderall increased by 67% and associated ED visits went up 
remarkably by 156% in adults while both trends remained unchanged in adolescents, 
suggesting different trends in different age groups. Third, physician was the major 
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source for the misused stimulants regardless of types of stimulants or age group. 
Also, those who used both Adderall and methylphenidate nonmedically were more 
likely to obtain the drugs from physician sources compared to those who used 
Adderall only. 
 There was a sharp increase in ADHD treatment rate in the U.S. in the late 
1990s (Olfson et al., 2003) and this increase continued until recent years (Visser et 
al., 2014; Zuvekas and Vitiello, 2012). Yet, our study showed that physician visits 
for Adderall and methylphenidates among adolescents aged 12-17 declined from 
2006 to 2011. One explanation for these discrepant findings is that the role of 
psychostimulants in treatment of ADHD has changed in recent years. Stimulants 
were used in 96% of visits in 2000, but only 87% of visits in 2010 (Garfield et al., 
2012). Another explanation is the introduction of new stimulants such as Vyvanse 
which has cut into the market for Adderall and methylphenidates.         
 Our study further showed that the reduction in methylphenidate prescription 
visits for adolescents was associated with decreased nonmedical use (although a 
causal association cannot be inferred). In contrast, nonmedical use of Adderall in 
adults increased, while prescription visits did not grow. The former finding is 
consistent with the theory that decreased availability of these medications through 
physician prescriptions may reduce nonmedical use of the drug (Komro and Toomey, 
2002). This conclusion, however, is not supported by the contrasting trends in 
Adderall prescriptions and nonmedical use in adults.  
 The differences in the temporal trends in nonmedical use of Adderall and 
methylphenidate open to a number of potential explanations, including differences in 
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pharmacological properties and in social factors. The extended-release formulation of 
Adderall has a longer duration of action than methylphenidate, producing a more 
steady effect (Markowitz et al., 2003). Furthermore, although both Adderall and 
methylphenidate increase CNS dopamine by blocking the dopamine transporter, 
Adderall additionally increases noreponephrine, which is associated with improved 
cognitive function (Pliszka et al., 1996). Since cognitive enhancement is the most 
commonly reported reason for nonmedical use of prescription stimulants (DeSantis 
and Hane, 2010; Teter et al., 2006; White et al., 2006), differences between Adderall 
and methylphenidate with regard to cognitive enhancement properties could partially 
explain Adderall’s increased popularity, especially among college students (Teter et 
al., 2006). 
 Social context in which the stimulant is used may also provide an explanation 
for nonmedical use trends. A 2010 multi-approach study of college students who 
reported nonmedical use of stimulants found that these students had limited 
knowledge of the physical or psychological effects of the drugs (DeSantis and Hane, 
2010). Also, about 36% of the stimulant users believed using Adderall could help 
them to be “smarter” and 89% of them got the drug from their friends. The reputation 
of Adderall on college campuses as “not harmful” and as means of “getting smart” 
may contribute to the increased rate of nonmedical use among adults.  
 Our study also found that adult ED visits involving Adderall showed a strong 
correlation with increased nonmedical use in adults. This finding is consistent with a 
previous DAWN report that found marked increase in ED visits involving ADHD 
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medications in adults, but not  adolescents (SAMHSA, 2013a).  Our study further 
revealed that this trend is limited to Adderall use among adult population. 
 Consistent with past research, our study found that a friend or relative was the 
major source for the nonmedically used ADHD stimulants (DeSantis and Hane, 
2010; Garnier-Dykstra et al., 2012; McCabe et al., 2006b; Teter et al., 2006; White et 
al., 2006). Our study further found that among those who obtained the drug from a 
friend or relative, more than 70% of them obtained their drug legitimately through a 
doctor’s prescription. This finding suggests that drug diversion plays a crucial role in 
nonmedical ADHD stimulant use. A study found that 61.7% of college students 
diagnosed with ADHD reported diverting their prescription stimulants (Garnier et al., 
2010). Additionally, those who used both Adderall and methylphenidate 
nonmedically were more likely than those with nonmedical Adderall use only to 
report obtaining the drug from physician sources, implying a heavier role of doctor 
shopping among these population. 
 The limitations of this study should be considered in interpreting the results. 
A major limitation was that the three datasets (NDTI, NSDUH, and DAWN) were 
not linked, which limited our capability to make further conclusion about the 
associations. For instance, we were not able to assess whether nonmedical use and 
ED visits happened among the same individuals who were prescribed these 
medications. Thus, causal inference from these data may be subject to “ecological 
fallacy”. Second, physician visits for methylphenidate and Adderall cannot directly 
represent the availability of these medications. Different dosages of medications may 
have been filled in each visit. Third, NSDUH used responses regarding the source of 
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nonmedically used stimulants in general to ascertain the source in those who reported 
using specific stimulants. Beginning in 2006, NSDUH asked specific question about 
nonmedically used Adderall; whereas, before 2006, nonmedically used Adderall was 
specified by participants’ report. Thus, the source question was asked among all 
nonmedical prescription stimulant users except for Adderall users. To assess the 
impact of this decision, we repeated the analyses limiting the data to year 2006 and 
after. The results were similar to the main analysis (data not shown), suggesting that 
changes in the ascertainment method did not influence the findings of the study. 
Fourth, the NSDUH relies on self-reports, whereas NDTI and DAWN rely on 
physicians’ reports, which may be vulnerable to recall bias. Finally, effects of the 
shifts in medical care policy or in drug market share may not be fully captured by 
these data.  
 
5. Conclusion 
 In the context of these limitations, the findings highlight the urgent need for 
public health campaigns to target drug diversion from legitimately prescribed users 
as physician prescriptions constitute the main source of nonmedically used ADHD 
stimulants. Clinicians should discuss the proper dispensation of the medications with 
their patients and educate them about their responsibilities regarding drug diversion. 
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Table 1. Characteristics of participants in samples examining trends in prescriptions, non-medical use and emergency department visits involving Adderall 
and methylphenidate using data from 2006-2011. 
 Prescriptions in treatment visitsb 
(National Disease and Therapeutic Index) 
Nonmedical use 
(National Survey on Drug Use and Health) 
Emergency department visits 
















N Wgt% (95%CI) N Wgt% (95%CI) N Wgt% (95%CI) N Wgt% (95%CI) N Wgt% (95%CI) N Wgt% (95%CI) 
Gender 
   Male 
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a. The age ranges for the public-access DAWN data are slightly different that those in other datasets. Participant ages in DAWN were 
categorized into ages 18-24, 25-34, 35-54, and ≥55 years. 







Table 2. Reasons for past-year emergency department visits involving Adderall or methylphenidate using the 




Adderall Methylphenidate  Adderall Methylphenidate  
N Wgt%(95%CI) N Wgt%(95%CI) N Wgt%(95%CI) N Wgt%(95%CI) 
 Nonmedical use 
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Table 3. Sources of stimulants for past-month nonmedical use of Adderall and 
methylphenidate using the National Survey on Drug Use and Health, 2006-2011. 
 
Sources 
Adderall  Methylphenidate  
N Wgt%(95%CI) N Wgt%(95%CI) 
Adolescent (Primary source) 
   Friend or relative 
   Physicians 
   Illegal     
   Others 



























   Friend or relative 
   Physicians 
   Illegal 





















Adult (Primary source) 
   Friend or relative 
   Physicians 
   Illegal     
   Others 

























Adult (Secondary source) 
   Friend or relative 
   Physicians 
   Illegal     























Figure 1A. Temporal trends in prescription, nonmedical use, and ED visits involving Adderall 
and methylphenidate among adolescents (12-17 years).  
Source: IMS National Disease and Therapeutic Index® , January 2006 to December 2012, 





































































































































Figure 1B. Temporal trends in prescription, nonmedical use, and ED visits involving Adderall 
and methylphenidate among adults (18 years old or above).  
Source: IMS National Disease and Therapeutic Index® , January 2006 to December 2012, 

































































































































Chapter 3. Sources of Nonmedically Used Prescription Stimulants: Differences 
in Recency and Severity of Misuse in a Population-Based Study 
Abstract 
Aim: Epidemiological data indicate that nonmedical use of prescription stimulants 
has increased over the past decade. However, little is known regarding the source of 
the misused stimulants and whether different sources correspond to differences in 
risk profiles and associated social and health problems. 
Method: Data from the 2006 to 2011 National Survey on Drug Use and Health were 
used. A total of 4,945 participants who used prescription stimulants nonmedically 
and also reported their source of misused stimulants were categorized by the source: 
friends/relatives source, physician source and illegal source. Logistic regression 
models were used to compare the socio-demographic, mental health and behavioral 
problems as well as stimulant use-related problems according to source of 
nonmedically used stimulants. 
Results: The most common sources of stimulants were friends/relatives, followed by 
physicians and illegal sources. Compared to participants reporting friends/relatives as 
the source, participants reporting an illegal source were more likely to be male, 
unemployed, have less than a high school education, a history of criminal behavior 
and began using stimulants at an earlier age. Participants reporting a physician source 
were more likely to have mental health problems and mental health service use. 
Higher odds of past-month stimulant use, frequent use (≥10 days per year), drug 
dependence and substance service use were found in individuals reporting physician 
and illegal sources. 
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Conclusions: Identifying the source of misused stimulants can be useful in detecting 
distinct subgroups of nonmedical prescription stimulant users. This, in turn, may be 
useful in the development of tailored preventive and treatment programs, and for 










Prescription drugs have been the second most commonly abused category of 
drugs behind marijuana (SAMHSA, 2012a). Prescription stimulants are a major 
contributor to this statistic. In 2012 about 1.2 million Americans reported using  
nonmedical prescription stimulants in the past year (SAMHSA, 2013a). There has 
been a remarkable growth in nonmedical use of these medications over the past 
decade particularly among young adults and adolescents (Arria and Wish, 2006; 
Boyd et al., 2006; McCabe et al., 2005; SAMHSA, 2009a; Teter et al., 2006).  
Previous studies have made a considerable contribution to investigating the 
epidemiology and risk factors associated with nonmedical use of prescription 
stimulants. In a recent review, the prevalence of past-year nonmedical prescription 
stimulant use ranged from 5% to 9% in adolescents and 5% to 35% in college-age 
adults (Wilens et al., 2008). College population studies have shown that the 
nonmedical prescription stimulant users are more likely to be male, white, members 
of fraternities and sororities, and earning lower GPAs (McCabe et al., 2005; Teter et 
al., 2006). The reported motives for use in this population range from cognitive 
enhancement and study aid to recreational use (Teter et al., 2005; White et al., 2006). 
Previous studies have consistently demonstrated that nonmedical prescription 
stimulant users are more likely to report other substance use and involvement of risky 
behaviors (McCabe et al., 2007a; McCabe et al., 2005; Teter et al., 2005).  
Previous studies have also revealed that a friend or relative was the major 
source for the nonmedically used prescription stimulants (DeSantis and Hane, 2010; 
Garnier-Dykstra et al., 2012; Garnier et al., 2010; McCabe et al., 2006b; White et al., 
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2006). Although apparent availability of stimulants over the Internet without a 
prescription has been reported (Schepis et al., 2008), the Internet remains a relatively 
minor source for prescription drugs as a whole (Inciardi et al., 2010).  
Little past research has investigated the implications of variations in specific 
source of nonmedically used stimulants. In particular, the implications for frequency, 
recency and severity of associated problems remain unexplored. This study attempted 
to fill the knowledge gap using data from the 2006 to 2011 National Survey on Drug 
Use and Health (NSDUH). More specifically, we sought to answer the following 
questions: 1) Do individuals reporting different sources of misused stimulants show 
different socio-demographic, mental health and behavioral profiles? and 2) Is the 
source of the nonmedically used stimulants associated with age of onset, recency and 




       We analyzed data from the NSDUH public use data files for 2006 to 2011 
(N= 338,495). We restricted our sample to participants who reported using 
prescription stimulants nonmedically in the past year after excluding those who used 
methamphetamine only (N=4,945). We conducted the analyses combining adolescent 
and adult data, as our previous analyses indicated few differences in sources of 
nonmedically used stimulants among adolescent and adult participants of NSDUH 
(data not shown). The NSDUH is an annual cross-sectional survey sponsored by the 
Substance Abuse and Mental Health Administration (SAMHSA) and is designed to 
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provide estimates of the prevalence of alcohol and drug use in the household 
population of the United States, 12 years of age and older. The survey employs a 50-
state design with an independent multistage area probability sample for each of the 
50 states and the District of Columbia. African-Americans, Hispanics, and youth are 
over-sampled to increase the precision of estimates for these groups. The response 
rate for household screening ranged from 87% to 91%, and for completed interviews 
from 74% to 76%, across the 6 years. Survey items were administered by computer-
assisted personal interviewing (CAPI) conducted by an interviewer and audio 
computer-assisted self-interviewing (ACASI) for sensitive questions. Use of ACASI 
was designed to provide respondents with highly private and confidential means of 
responding to questions and to increase the level of honest reporting of illegal drug 
use and other sensitive behaviors. Respondents were offered a $30 incentive payment 
for participation in the survey. Detailed information about the sampling and survey 
methodology of NSDUH can be found elsewhere (SAMHSA, 2007, 2008, 2009b, 
2010, 2011, 2012).  
2.2. Assessments 
2.2.1. Nonmedical prescription stimulant use  
      Lifetime nonmedical prescription stimulant use was ascertained through the 
use of a specified list of stimulants. To aid recall, pictures of the medications were 
provided. The stimulants include Ritalin or methylphenidate, amphetamines, 
dextroamphetamine, Cylert, methamphetamine, Methedrine or Desoxyn, Dexedrine, 
and selected diet pills. Participants were asked: “Have you ever, even once, used 
[Drug name] that was not prescribed for you or that you took only for the experience 
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or feeling it caused?” Participants were also asked if they had used any other 
stimulants. We further ascertained past-year prescription stimulant use if the 
respondents answered positively to the above question and indicated that the time 
since last use was within 12 months. 
2.2.2. Sources of misused stimulants 
       NSDUH respondents who reported using prescription stimulants 
nonmedically in the past 12 months were asked a series of questions on how they had 
obtained these drugs most recently. The 10 mutually exclusive choices were 
categorized into the following 3 groups: friend/relative source (“got from friend or 
relative for free,” “bought from friend or relative” or “took friend or relative without 
asking”), physician source (“got from one doctor” or “got from more than one 
doctor”), and illegal source (“bought from drug dealer or other stranger,” “bought on 
the internet,” “wrote fake prescription,” “stole from doctor’s office, clinic, hospital, 
or pharmacy”). We excluded those who reported other source from the analyses as 
the source was not specified.   
2.2.3. Socio-demographic characteristics 
       Socio-demographic variables included in the analyses were sex, age (12-17, 
18-25, ≥ 26), race/ethnicity (non-Hispanic white, minorities), and annual household 
income (≤ $19,999, $20,000-$34,999, $ 35,000-$69,999, ≥ $70,000). For adults aged 
18 and above we additionally included marital status (single, non-single), 
employment status (partial or full employment, unemployed, not in labor force), 
education (less than high school, high school, college and above). 
2.2.4. Past-year criminal behaviors, mental health and substance use problems 
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Participants self-reported how many times they had attacked someone with 
the intent to seriously hurting them, how many times they had sold illegal drugs, and 
how many times they had stolen or tried to steal anything worth more than $50 in the 
past year. Consistent with past research (Martins et al., 2006; Martins et al., 2009), 
participants who reported any of the three behaviors were categorized as having 
criminal behavior (0 for none of these behaviors and 1 for engaging in these 
behaviors 1 time or more). Past-year arrest was created to capture involvement with 
the law and justice systems. Based on  the number of times in the past 12 months 
respondents had been arrested and booked for breaking the law, without counting 
minor traffic violations, past year arrest was categorized as 0 for none and 1 for more 
than once. In a section on health care, participants were asked if in the past year they 
had been told by a medical doctor or health care professional that they had an anxiety 
disorder or depression and whether they received any mental health treatment or 
substance use disorder treatment in the past year. The NSDUH team created separate 
indicators for past-year alcohol and drug dependence based on the responses to items 
that assessed the Diagnostic and Statistical Manual of Mental Disorders–IV (DSM-
IV) criteria for eight illicit drugs (American Psychiatric Association, 1994). A 
composite illegal drug dependence measure that did not include stimulants was used 
in this report.  
2.2.5. Onset, recency and severity of nonmedical use of stimulants 
      Early onset of stimulant use was defined by first time of use before or at age 
13, which is a similar definition as has been used in previous work (Grant and 
Dawson, 1998). Past-month stimulant use was ascertained by use within the past 30 
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days. Stimulant use disorder included both stimulant abuse and dependence, defined 
based on criteria specified in the DSM-IV (American Psychiatric Association, 1994). 
Frequency of use in the past month or year was a free response question in which 
participants entered the exact number of days the substance was used. We defined 
frequent use as using stimulant more than 10 days in the past year, consistent with 
past literature (Schepis and Krishnan-Sarin, 2009).  
2.3. Statistical analyses 
       Analyses focused on exploring differences between the three past-year 
nonmedical prescription stimulant user groups categorized by their main source:  a 
friends/relatives, physician, or illegal source group. The group of friends/relatives 
source, the largest group, was set as the reference category. We used a series of 
logistic regression models to compare the groups with regard to socio-demographic 
characteristics, mental health problems, mental health and substance disorder service 
use, criminal behaviors and substance dependence. Another set of models examined 
the onset, recency, and severity of stimulant use in each of these groups. The adjusted 
models were controlled for age, sex, race-ethnicity, education, marital status, 
employment status, household income, past-year clinician-identified depression, 
anxiety disorders, criminal behaviors, and arrest. Mental health and substance service 
use were not adjusted for due to potential collinearity with mental health variables.  
     All percentages reported are weighted and Taylor series linearization was 
used to take into account the complex survey design of NSDUH. Stata 13 was used 





3.1. Sources of nonmedically used prescription stimulants 
       About 7.8% (n = 24,224) of participants from NSDUH 2006-2011 reported 
lifetime nonmedical use of prescription stimulants, and 1.1% (n=6,384) reported use 
in the past year. A specific source of misused stimulants was identified by 4,945 
respondents, including 3,772 adults and 1,173 adolescents. The most commonly 
reported specific sources were getting from a friend/relative for free (52.5%), buying 
from a friend/relative (17.5%), and getting from just one doctor (10.3%) (Table 1). 
There was a relatively small proportion of prescription stimulant users who reported 
getting the medication from more than one doctor (2.9%) or the internet (1.8%). 
When these sources were summarized into the four predefined categories, the most 
commonly reported sources were friends/relatives sources (75.1%), followed by 
physicians (11.2%), illegal sources (9.8%), and then other sources (3.9%).  
3.2. Correlates of source of nonmedically used prescription stimulants 
       Participants reporting an illegal source were predominantly male (58.3%), 
while no sex difference was observed in the other two groups (Table 2). Participants 
reporting a physician source or illegal source were more likely to be aged 12-17 (vs 
aged 18-25) compared to those reporting a friends/relatives source. 
       Compared to the group who obtained stimulants from friends/relatives, the 
illegal source group was significantly less likely to be female (Odds ratio [OR] 0.48, 
95% confidence interval [95% CI]: 0.32, 0.72), have college or above education (OR: 
0.37, 95% CI: 0.20, 0.69) and more likely to be unemployed (OR: 2.79, 95% CI: 
1.18, 6.60) The illegal source group also had higher odds of criminal behaviors (OR: 
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2.62, 95% CI: 1.67, 4.10), and arrest (OR: 2.27, 95% CI: 1.47, 3.49) (Table 2). The 
physician source group was more likely to report clinically-identified depression 
(OR: 1.63, 95% CI: 1.05, 2.52), an anxiety disorder (OR: 4.37, 95% CI: 2.66, 7.18) 
and receiving mental health treatment (OR: 2.92, 95% CI: 1.96, 4.35). Both the 
physician source and the illegal source groups were more likely to meet the criteria 
for drug dependence (physician OR: 1.73, 95% CI: 1.15, 2.61; illegal OR: 2.36, 95% 
CI: 1.52, 3.66) and to receive substance abuse treatment in the past year (physician 
OR: 2.10, 95% CI: 1.30, 3.39; illegal OR: 2.50, 95% CI: 1.49, 4.18).   
3.3. Stimulant use onset, recency, and severity  
       In the adjusted model, the physician source group was more likely to report 
past-month stimulant use (aOR: 3.29, 95% CI: 2.24, 4.85), frequent use (≥10 days in 
the past year) (aOR: 3.07, 95% CI: 1.95, 4.82), and to meet the criteria for a 
stimulant use disorder (aOR: 2.75, 95% CI: 1.52, 4.97) compared to the 
friends/relatives source group. The illegal source group was more likely to report 
early onset (onset ≤ age 13) (aOR: 2.07, 95% CI: 1.02, 4.15), past-month use (aOR: 
1.55, 95% CI: 1.00, 2.40), frequent use (aOR: 2.21, 95% CI: 1.45, 3.38) and to meet 
the stimulant use disorder criteria (aOR: 2.69, 95% CI: [1.80, 4.01) compared to the 
friends/relatives source group. We conducted pair-wise comparisons between the 
physician source and the illegal source groups. In these comparisons, the physician 
source group was found to be more likely to report past-month use compared to the 






To the best of our knowledge, this is the first study using nationally 
representative data to examine the implications of the sources of nonmedically used 
stimulants with regard to socio-demographic and mental health characteristics of 
users and also seriousness of prescription stimulant use. Consistent with past research 
(DeSantis and Hane, 2010; Garnier-Dykstra et al., 2012; McCabe et al., 2006; White 
et al., 2006), friends/relatives were the major sources of misused stimulants, 
constituting 78.1% of all users. In addition, the internet appeared to be a relatively 
minor source of prescription stimulants regardless of the fact that there is widespread 
prescription drug availability via websites (McCabe and Boyd, 2005; Schepis and 
Krishnan-Sarin, 2009). Although doctor-shopping has been recognized as a 
dangerous signal for prescription drug fatalities (Hall et al., 2008), only 0.7% of 
study population reported prescriptions from more than one doctor as the source of 
their nonmedically used stimulants.    
Those who reported an illegal source for their stimulants were more likely 
than those obtaining the drug from friends/relatives to be male, unemployed, and less 
likely to have a higher education. They were also more than two times as likely to 
report criminal behaviors and an experience of being arrested. This group, however, 
comprised only 10.2% of all nonmedical prescription stimulant users. Consistent 
with this finding, other research based upon NSDUH data found that adolescents who 
purchased their misused prescription drugs illegally had a worse risk profile in terms 
of concurrent substance use and severity of prescription misuse, regardless of the 
classes of prescription drugs purchased (Schepis and Krishnan-Sarin, 2009).  
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The physician source group had markedly greater mental health burden 
including depression, anxiety disorder, and mental health service use compared to the 
friends/relatives source group. This finding could indicate the use of prescription 
stimulants for self-medication by some in this group. In another study, up to 50% of 
frequent nonmedical prescription stimulant users reported depressed mood (Teter et 
al., 2010). Additionally, many users self-diagnose themselves as having an attention 
disorder (Judson and Langdon, 2009). In a 2009 survey study, 39% of college 
students who misused stimulants did so with the desire to self-treat target symptom 
such as concentration (McCabe et al., 2009). It is also possible that the some 
stimulant users developed psychological problems after misusing the drugs. Many 
stimulants, including methylphenidates and mixed amphetamines, have been shown 
to increase the risk of psychosis or mania (Chakraborty and Grover, 2011; Mosholder 
et al., 2009). Our finding underscores the significance of screening for mental health 
disorders among the nonmedical prescription stimulant users, particularly among 
those who report obtaining these drugs from physicians.  
Obtaining stimulants from physicians or via illegal methods were both 
strongly correlated with recent use (in the past month), frequent use (more than 10 
days in the past year) as well as meeting stimulant use disorder criteria. Those 
obtaining these drugs via illegal methods were more likely to report an early-onset of 
their stimulant use. Early onset of any substance use has been found to be linked to 
subsequent dependence on other drugs (Anthony and Petronis, 1995); thus, it is not 
surprising that the illegal source group was also more likely to have other drug 
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dependence and substance disorder service use compared to the friends/relatives 
source group.  
The finding that the physician source group had significantly higher odds of 
stimulant use problems and particularly past-month use is intriguing. It is possible 
that a physician is a more sustainable source of drugs, leading users who obtain their 
misused drug from this source to continue using, which in turn may then eventually 
lead to a stimulant use disorder. On the other hand, the psychological vulnerabilities 
of this group may contribute to the persistent use of stimulants for self-medication. 
The more serious and persistent nature of stimulant misuse among individuals who 
report obtaining their drugs from physicians points to the need for better monitoring 
of dispensation and use of these drugs in medical practice. In one study, almost half 
of physicians found it difficult to discuss the abuse potential of prescription drugs 
with their patients (McCabe et al., 2002). This finding suggests that physicians 
should receive more training to identify nonmedical users, to discuss the potential 
danger of the stimulants, and to educate their patients regarding the risks associated 
with misuse and the legal responsibility of drug diversion.  
In clinical practice, identifying the source of misused stimulants may also 
serve as a useful indicator of the specific needs and vulnerabilities of the patients. For 
example, patients who report obtaining their misused stimulants illegally or from 
doctors appear to be an increased risk of other substance use disorders. Those who 
report obtaining their misused stimulants from a physician should be screened for 
depression, anxiety or other mental health problems.  
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Several limitations to this study and the NSDUH data should be noted. First, 
the NSDUH asks for the most recent source of misused stimulants, but not the most 
commonly used source. Second, Adderall, a commonly used stimulant, was not 
included in the list of stimulants specifically enquired about and was included in the 
“other stimulants.” There is some evidence that this approach to ascertaining 
Adderall may have missed a large proportion of Adderall user (Kroutil et al., 2010). 
Third, given the cross-sectional nature of the NSDUH, causal-relationship cannot be 
established here. Thus, for example, it is not clear from these data whether mental 
health problems preceded or followed stimulant misuse. Fourth, all of the data were 
based on self-report, which is open to recall or social-desirability bias. However, the 
validity of these reports has been established in a previous study (Harrison, 2007). 
Fifth, the mental health variables (depression, anxiety) used here were based on 
clinician-diagnoses communicated to the participants, which is conditional to having 
had contact with a clinician. This factor may also, at least partly, explain the 
association of physician source with these mental health indicators.  Finally, 
questions used by the NSDUH do not differentiate between those who obtained their 
stimulant from friends versus relatives, and the implications and correlates of these 
two sources may be different (Schepis and Krishnan-Sarin, 2009). 
 
5. Conclusion 
Despite these limitations, findings from this study suggest that different 
sources of misused stimulants are associated with different risk profiles and stimulant 
use involvement. Those who obtained their misused stimulant from a physician 
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source carry a greater burden of mental health problems, whereas there is a stronger 
correlation between criminal activities and obtaining stimulants from illegal sources. 
Both these groups tend to have more serious stimulant use problems than the group 
who obtained their stimulants from friends or relatives.  The implications of these 
differences in the source of misused stimulants may inform future prevention and 




Table 1. Different types of prescription stimulant sources of past-year nonmedical prescription 
stimulant users in a sample of the US population aged 12 and above (N= 4,945): data from 











Friends/relatives source 3813 75.1(72.8,77.3) 
Got the stimulants from a friend or relative for free 2480 52.5 (50.2,54.9) 
Bought the stimulants from a friend or relative 1044 7.5 (15.9,19.3) 
Took the stimulants from a friend or relative without asking 289 5.0 (4.1,6.2) 
Physician source 475 11.2(9.8,12.6) 




Got prescriptions for stimulants from more than one doctor  48 2.9 (0.6,1.5) 
Illegal source 485 9.8(8.1,11.5) 
Wrote fake prescriptions for stimulants  20 0.5 (0.2,1.2) 
Stole the stimulants from a doctor’s office, clinic, hospital, or 
pharmacy  
38 0.9 (0.5,1.6) 
Bought the stimulants from a drug dealer or other stranger   363 6.7 (5.5,8.0) 
Bought the stimulants on the Internet  64 1.8 (1.2,2.6) 
Other source 172 3.9 (2.9,5.3) 










Table 2. Characteristics of past-year nonmedical ADHD stimulant based on source of misused 
stimulants in a sample of the US population aged 12 and above (N= 4,773): data from 2006–2011 
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*p<0.05, †p<0.01, ‡ p<0.001 
a. Education, marital status, and employment status were examined in adults aged 18 and 























Table 3. Onset, recency and severity of past-year nonmedical prescription stimulant use based on source of misused stimulants in a sample of the US 
population aged 12 and above (N= 4,773): data from 2006–2011 National Survey on Drug Use and Health. 
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*p<0.05, †p<0.01, ‡ p<0.001 
a. Adjusted models were adjusted for sex, age race, education, marital status, employment, income, past-year major depression, anxiety disorder, 




Chapter 4. Part A. Patterns of Concurrent Substance Use Among  
Adolescent Nonmedical ADHD Stimulant Users 
Abstract 
Objective: To identify subgroups of adolescents with nonmedical ADHD stimulant 
use according to patterns of concurrent problematic substance use.  
Method: We used latent class analysis (LCA) to identify subgroups with concurrent 
problematic substance use ( i.e. had any criteria of abuse or dependence)  in a sample 
of 2,203 adolescent participants from the National Surveys on Drug Use and Health 
2006-2011 who reported past-year nonmedical use of ADHD stimulants. 
Multivariate latent regression was used to assess the association of socio-
demographic, mental health, deviant behavior, and service use characteristics with 
the latent classes.  
Results: The best model fit was a four-class model, including a large class with 
frequent concurrent use of alcohol and marijuana (Alcohol/Marijuana class; 41.2%), 
a second large class with infrequent use of other substances (Low substance class, 
36.3%), a third class characterized by more frequent misuse of prescription drugs 
(Prescription drug class; 14.8%), and finally a class characterized by problematic use 
of multiple substances (Multiple substances class; 7.7%). These four classes showed 
distinct socio-demographic and mental health profiles. Compared with individuals in 
Low substance class, those in the other three classes were all more likely to report 
mental health problems, deviant behaviors, mental and substance service use, with 
Multiple substances class being most likely to report social and behavioral problems.  
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Conclusions: Adolescent nonmedical ADHD stimulants users are a heterogeneous 
group with distinct classes with regard to mental health comorbidity, behavioral 
problems and service use. The findings have implications for planning a more 
tailored prevention and treatment programs based on their concurrent substance use 






















       Nonmedical use of prescription stimulants, especially stimulants prescribed 
for treatment of Attention Deficit Hyperactivity Disorder (ADHD), has received 
increased research attention in the past decade (McCabe et al., 2007a; McCabe et al., 
2007b; McCabe et al., 2005; Safer, 2000; Safer et al., 1996; Teter et al., 2005; Teter 
et al., 2006; White et al., 2006). These stimulants, including methylphenidate and 
mixed salts amphetamines, remain the first line of pharmacotherapy for ADHD 
(Olfson et al., 2003; Zito et al., 2003) and were classified as schedule II substances in 
the US Controlled Substances Act (CSA) due to their high abuse potential (Drug 
Enforcement Administration, 2003a). 
       Much of past research has focused on nonmedical prescription stimulant use 
among young adults (Arria et al., 2008; Garnier-Dykstra et al., 2012; Johnston, 2003; 
McCabe et al., 2009; McCabe et al., 2005; McCabe et al., 2007c; SAMHSA, 2009a; 
Teter et al., 2005; Teter et al., 2006; White et al., 2006. However, there is also 
evidence of a growing problem of nonmedical use among adolescents (Arria and 
Wish, 2006; Boyd et al., 2006, 2007; McCabe et al., 2007a; McCabe et al., 2004). 
According to data from the Monitoring The Future (MTF) survey, past-year 
nonmedical use of methylphenidate in high school seniors increased from 0.5% in 
1995 to 2.5% in 2002 (Arria and Wish, 2006).  A more recent report showed a 
continued growth between 2008 and 2013 found an increase from 6.8% to 8.7% in 
past-year nonmedical use and from 2.9% to 4.1% in current use of amphetamines in 
12th graders in this time period (Wadley, 2013). In a high school survey, 4.5% of 
students reported using prescription stimulants nonmedically, with 23.3% reporting 
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being approached to sell, give, or trade these drugs (McCabe et al., 2004). 
Emergency room visits involving ADHD stimulants tripled in the period between 
2005 and 2010 highlighting the health burden of nonmedical use of these 
medications (SAMHSA, 2013b).    
There is also growing evidence that nonmedical ADHD stimulant users are 
more likely to use other substances or to engage in risky behaviors (Boyd et al., 
2006; McCabe et al., 2007a; McCabe et al., 2006a; McCabe et al., 2004; SAMHSA, 
2009a). Among high school students, nonmedical prescription stimulant users 
reported significantly higher rates of alcohol and other drug use than nonusers 
(McCabe et al., 2004). Based on a report using the National Survey on Drug Use and 
Health (NSDUH), 90 percent of college students who had past-year nonmedical 
Adderall use also reported past-month binge drinking, more than half being heavy 
drinkers (SAMHSA, 2009a). In another survey conducted in 119 colleges in the 
United States, nonmedical prescription stimulant users were more likely to report use 
of alcohol, cigarettes, marijuana, ecstasy, cocaine and engaging in other risky 
behaviors (McCabe et al., 2005). Concurrent use of substances has been generally 
shown to be associated with worse psychological and social consequences in young 
adults (Barrett et al., 2006; Grant and Harford, 1990; Hedden et al., 2009). However, 
relatively little is known regarding the concurrent substance use patterns among 
adolescent who use prescription stimulants nonmedically (Barrett et al., 2006; Grant 
and Harford, 1990; Hedden et al., 2009). In particular, it is not clear whether 
concurrent use of other substances is common among all nonmedical users of 
stimulants, or simply exists in certain subgroups. Identifying subgroups of ADHD 
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stimulant users based on concurrent substance use has implications for the study of 
the epidemiology of nonmedical stimulant use, which can help to identify youth who 
are at particularly high risk of other substance use.  
In this study, we used data from national surveys of general population 
adolescents who use stimulants nonmedically to explore subgroups according to 
concurrent problematic substance use patterns, including alcohol and illegal drugs, 
using latent class analysis. We further examined variations in socio-demographic 
characteristics, mental health profiles, deviant behaviors, and service use among the 
empirically identified classes. We hypothesized that there exist at least 2 subgroups of 
nonmedical stimulant users, one with lower prevalence of other substance use who 
may be using stimulants for improving attention and concentration and, perhaps as a 
study aid, and uses few other substances, and another group who abuses these drugs 
recreationally and is likely to use other substances concurrently. 
 
2. Methods 
2.1. Study sample and measures 
       Combined annual data from the NSDUH public use data files for the years 
2006 to 2011 (N= 338,495) were analyzed. The study sample was restricted to adult 
participants aged 12 to 17 (N=109,466) who reported using ADHD medications 
nonmedically in the past year (N=2,203). The NSDUH is an annual cross-sectional 
survey sponsored by the Substance Abuse and Mental Health Administration 
(SAMHSA) and is designed to provide estimates of the prevalence of alcohol and 
drug use in the household population of the United States, 12 years of age and older. 
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The survey employs a 50-state design with an independent multistage area 
probability sample for each of the 50 states and the District of Columbia. African-
Americans, Hispanics, and youth are over-sampled to increase the precision of 
estimates for these groups. The response rate for household screening ranged from 
87% to 91% and for completed interviews from 74% to 76% across the 6 years.  
       Survey items were administered by computer-assisted personal interviewing 
(CAPI) conducted by an interviewer and audio computer-assisted self-interviewing 
(ACASI) for sensitive questions. Use of ACASI was designed to provide participants 
with a highly private and confidential means of responding to questions and to 
increase the validity of reporting of illegal drug use and other sensitive behaviors. 
Participants were offered a $30 incentive payment for participation in the survey. 
Detailed information about the sampling and survey methodology of the NSDUH are 
found elsewhere (SAMHSA, 2007, 2008, 2009, 2010, 2011, 2012).  
2.2. Assessments 
2.2.1. Assessment of past-year nonmedical ADHD stimulant use  
       For the current analyses, ADHD stimulants were defined as stimulants with 
specific indications for treatment of ADHD, and included Ritalin®  or 
methylphenidate, Cylert® , Dexedrine® , Dextroamphetamine, Adderall® , and 
Vyvanse® . The survey used the following question to assess nonmedical use of any 
ADHD stimulants in the lifetime: “Have you ever, even once, used [Drug name] that 
was not prescribed for you or that you took only for the experience or feeling it 
caused?” Nonmedical ADHD stimulant use was defined as past-year if their time 
since last use was within the prior 12 months.  
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2.2.2. Assessment of socio-demographic characteristics 
Socio-demographic variables included in the analyses were sex, age (12-13, 
14-15, 16-17), race/ethnicity (non-Hispanic white, racial/ethnic minority), school 
dropout, average grade (C and above, D or lower) in the last period completed, and 
annual household income (≤ $19,999, $20,000-$34,999, $35,000-$69,999, ≥ 
$70,000).  
2.2.3. Assessment of past-year problematic substances use 
Past-year problematic substance use was defined by fulfilling any of the 
criteria for past-year substance abuse or dependence based on the Diagnostic and 
Statistical Manual of Mental Disorders –IV (DSM-IV) (American Psychiatric 
Association, 1994). The substances examined included alcohol, marijuana, cocaine, 
heroin, hallucinogens, inhalants, prescription opioids, and tranquilizers/sedatives 
(combined). Participants who endorsed any criteria of abuse or dependence for these 
substances and specified their recent use in the past 12 months were categorized as 
past-year problematic users.  
2.2.4. Assessment of past-year mental health and deviant behavior variables 
Mental health variables included were past-year anxiety disorder and major 
depressive disorder (MDD), as ascertained by participants’ self-report of past-year 
diagnosis by a medical doctor or health care professional. Past-year mental health 
and substance abuse service use were ascertained by asking participants whether they 
received any mental health treatment or substance abuse treatment in the past year. 
Past-year deviant behaviors were assessed by asking the participants how many times 
they had attacked someone with the intent to seriously hurting them, how many times 
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they had sold illegal drugs, and how many times they had stolen or tried to steal 
anything worth more than $50 in that time frame. Consistent with past research 
(Martins et al., 2006; Martins et al., 2009),  participants who reported any of the four 
behaviors were categorized as having “deviant behaviors” (0 for none of these 
behaviors and 1 for engaging in one of more of these behaviors at least once). Past-
year incarceration was assessed by asking participants how many times in the past 12 
months they had been arrested and charged with breaking the law without counting 
minor traffic violations (0 for none and 1 for at least once). Past-year sexually 
transmitted disease (STD) was also assessed by participant self-reports of diagnosis 
by a medical doctor or health care professional. 
2.3. Statistical analyses 
Complex latent class analysis (LCA) was used to identify subgroups 
according to concurrent problematic substance use among individuals who used 
ADHD stimulants nonmedically in the past year. We performed LCA for 1 to 6 
classes in order to ascertain the model with the optimal fit. Minimum values of the 
Bayesian Information Criterion (BIC) was given priority over other fit statistics such 
as Akaikes Information Criterion (AIC) and Sample Size Adjusted BIC (ABIC), 
given its more stable performance in simulation studies (Nylund et al., 2007). We 
also considered the class size and clinical interpretability in selecting the model.  
LCA was applied using the Mplus software (Muthén, 1998-2010). We chose 
eight dichotomous substance use variables (past-year problematic use of alcohol, 
marijuana, cocaine, heroin, hallucinogens, inhalants, prescription opioids, and 
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tranquilizers/sedatives) to empirically determine the smallest number of classes with 
similar drug use patterns that explain the response pattern in the data.  
Once the number of classes was ascertained, correlates including socio-
demographics, mental health and deviant behaviors were incorporated into the 
models using unadjusted and adjusted multinomial regression models. These 
analyses were conducted using a modal assignment latent regression approach with 
Stata 13.0 software (StataCorp, 2013). All analyses included adjustment for the 
complex survey design by taking into account the survey weights, clustering and 
stratification. All the percentages reported are weighted. A p<0.05 was used to 
ascertain the statistical significance of findings.  
 
3. Results 
3.1. Characteristics of the nonmedical ADHD stimulant users 
       The frequency distribution of participant characteristics is presented in Table 
1. Approximately 3.2% (n = 2,203) of adolescent participants from the NSDUH 
reported nonmedical use of ADHD stimulants in the past year. A relatively higher 
percent of nonmedical ADHD stimulant use was found among females (51.8%), aged 
16-17 (64.2%), whites (80.7%), and with a household income < $20,000 (39.9%). 
Our adjusted logistic regression analyses further showed that they were more likely 
to be female (adjusted odds ratio, aOR=1.46, 95%CI [1.30,1.65]), aged 16-17 versus 
aged 12-13 (aOR=6.93,[5.45,8.81]), white versus in minority 
(aOR=0.29,[0.24,0.36]), to have grade D or lower (aOR=1.35,[1.07,1.70]), to come 
from family with household income ≥ $75,000 (aOR=1.40,[1.11,1.77]). They were 
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also more likely to report depression (aOR=1.60, [1.31,1.95]), anxiety disorder 
(aOR=1.31, [1.00,1.71]), to have received mental health treatment (aOR=1.38, 
[1.19,1.60]) and SUD treatment (aOR=2.90, [2.30, 3.66]), to report deviant behaviors 
(aOR=6.60, [5.69,7.66]), incarceration (aOR=2.03, [1.65,2.50]), and sexually 
transmitted disease (aOR=1.63,[1.06,2.50]) in the past year.  
3.2. Subtypes of nonmedical ADHD stimulant users by LCA  
       The most commonly used substance among nonmedical ADHD stimulant 
users was alcohol (53.3%), followed by marijuana (47.9%), pain relievers (23.4%), 
hallucinogens (12.4%), tranquilizers and sedatives (9.9%), cocaine (7.3%), inhalants 
(5.8%) and heroin (1.7%). 
       Latent class analysis was performed for 1 to 7 class models. The fit statistics 
of BIC was lowest for the 4-class model and the AIC and ABIC for the 4 class model 
were similar to the 5-class model (Appendix 2), suggesting that the minimum fit 
index values were obtained for the 4-class model.(Nylund et al., 2007). By taking 
into account the minimum value of BIC as well as the clinical interpretability, a 4-
class model was selected. Fit statistics were shown in Appendix Table 2. 
       Figure 1 presents prevalence of problematic use of different substances in the 
four classes of nonmedical ADHD stimulant users. Class 1 constituted 36.3% of the 
sample was comprised of individuals with low probabilities of problematic use of 
alcohol and prescription opioids and near zero probabilities of other problematic 
substance use (Low substance class). Class 2 made up 14.8% of the study sample and 
included individuals with moderate probabilities of problematic use of alcohol and 
marijuana, but additionally included participants with high probabilities of 
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problematic use of pain relievers and sedatives/tranquilizers (Prescription drug 
class). Class 3 included individuals with remarkably high probabilities of problematic 
use of marijuana and alcohol and was the largest class (Alcohol/marijuana class, 
41.2%). Finally, class 4 was comprised of individuals who had the highest 
probabilities of problematic use of most of the substances examined (Multiple 
substance class, 7.7%). 
3.3. Characteristic of participants in the LCA-defined classes  
       Table 2 presents the socio-demographic, mental health, service use and 
deviant behavior profiles of the 4 classes of past-year nonmedical ADHD stimulant 
users. Prescription drug, Alcohol/marijuana, and Multiple substance classes showed 
particularly high prevalence of deviant behaviors (Prescription drug: 64.8%; 
Alcohol/marijuana: 60.3%; Multiple substance: 85.5%) and incarceration 
(Prescription drug: 26.3%; Alcohol/marijuana: 23.6%; Multiple substance: 34.2%). 
Furthermore, 46.4% of those in Prescription drug class reported past-year mental 
health service use and 27.1% reported a depression diagnosis.  
       Results from the unadjusted and adjusted latent regression models comparing 
participants in the latent classes with those in Low substance class as the reference 
category are presented in Table 3. Compared to the Low substance class, participants 
in the Prescription drug class were more likely to be female (aOR=1.56, [1.17,2.10]). 
Participants in the Alcohol/marijuana and Multiple substance classes were more 
likely to be in the 16-17 years age group vs. the 12-13 year group. Furthermore, all 
these three classes were significantly more likely than the Low substance class to 
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have average grades of D or lower. Multiple substance class was more likely to 
report school dropouts (aOR=2.62, [1.29,5.34]).   
       Relative to the Low substance class, the other three classes were associated 
with higher odds of clinician-identified depression, mental health and substance 
service use, deviant behaviors and incarceration. Prescription drug and Multiple 
substance class were additionally associated with higher odds of clinician-identified 
anxiety disorder. Multiple substance class showed particularly higher odds of 
substance treatment, deviant behaviors and incarceration. 
 
4. Discussion 
The present study found that approximately 3.2% of adolescents aged 12-17 
in the general household population reported past-year nonmedical use of 
prescription stimulants. Among them, more than half reported concurrent 
problematic substance use with the most frequently used being alcohol (53.3% of 
nonmedical ADHD stimulant users), marijuana (47.9%) and pain relievers (23.4%). 
Furthermore, this study found that with regard to concurrent problematic substance 
use, nonmedical ADHD stimulant users are a heterogeneous group which 
encompasses four classes with distinct psychiatric and social profiles, which has 
value for risk evaluation and preventive strategy development.  
The classes that we labeled as Prescription drug, Alcohol/marijuana and 
Multiple substance classes were all more likely to report mental health problems, 
mental health and substance service use, and deviant behaviors compared to the Low 
substance class, which had the lowest prevalence of concurrent problematic 
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substance use. Previous studies have found relationships between nonmedical use of 
prescription stimulants and presence of depressed mood among youth (Compton et 
al., 2006; Poulin, 2007; Teter et al., 2010). Our study further points out that the 
association with mood disorders may be more pronounced in the subgroups that 
report more concurrent problematic substance use. Considering individuals with co-
occurring mental and substance disorders have been found to have higher rate of 
service use than those without co-occurring disorders (Chen et al., 2013; Wang et al., 
2005), higher prevalence of mental and substance service use was also observed in 
the three classes. Our finding underscores the significance of screening for mental 
problems among the nonmedical ADHD stimulant users.  
       The findings of greater deviant behaviors and poorer academic performance 
among the three classes which used more substances are particularly noteworthy. 
Consistent with previous reports in college students, we found nonmedical 
prescription stimulant users with poorer academic performances among adolescents, 
which broke the myth that prescription stimulants work well as a study aid (Arria, 
2008; Garnier-Dykstra et al., 2012; McCabe et al., 2004). The underlying reasons for 
decreased academic performance remains uncertain (Arria and DuPont, 2010), this 
study provides evidence that involvement in more problematic substance use may 
contribute to this phenomenon despite that temporal relationship could be not 
established. The motives for stimulant use may also vary considerably among 
stimulant users with and without concurrent other substance use (McCabe and 
Cranford, 2012). These differences call for a more nuanced approach to prevention 
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and treatment of adolescents with nonmedical stimulant use based on concurrent use 
of other substances and motives for their stimulant use.  
Despite the similarities among the three classes with higher prevalence of 
concurrent substance use problems with regard to psychiatric and behavior profiles, 
these three classes showed some differences in socio-demographic profiles. Most 
notably, participants in the Prescription drug class, consisting of 14.8% of our study 
population, were more likely to be female compared to the Low substance use class, 
while the other two classes did not show such gender differences. This finding is 
consistent with past research which has found that females are at increased risk for 
nonmedical opioid and tranquilizers use (Roe et al., 2002; Simoni-Wastila, 2000).  
        Compared to the Low substance class, the Multiple substance class had 
exceptional higher odds of reporting mental health problems, mental and substance 
service use and behavior problems. Comorbid substance use and psychiatric 
disorders confer an additional risk for not only worse social outcomes but also and 
poorer treatment response (Cuffel et al., 1994; Grella et al., 2001; Hasin et al., 2007b; 
Strain, 2002a). Similarly, concurrent use of multiple substances is linked to more 
physical consequences and criminal involvement (Hasin et al., 2007b; Hedden et al., 
2009). Considering the fact that adolescents in this class were also more likely to 
drop out of school, prevention efforts targeted to adolescents at risk of dropping out 
of schools might improve the psychiatric, social, and health outcomes of this 
population.  
       This study has multiple strengths, including a large sample size and 
generalizability to the US household population. However, the result should be 
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interpreted with caution due to the limitations of the study and of the NSDUH data. 
First, all the information were based on self-report, which is prone to recall and other 
reporting biases, although the validity of substance use reports in NSDUH has been 
established previously (Harrison, 2007). Second, the cross-sectional survey data 
limits assessment of temporal relationships and causal inferences. Third, we used 
clinician-identified depression and anxiety in this study, which are subject to health 
service access and availability. Lastly, the information regarding the frequency of 
nonmedical prescription stimulant use was not available, thus whether these 
subgroups differ by their level of severity remains unknown.    
 
5. Conclusion 
        Our results suggest that adolescents who use ADHD stimulants nonmedically 
are not a homogeneous group. Rather, they comprise subgroups with distinct profiles 
with regard to concurrent substance use, socio-demographic characteristics, academic 
performance and mental health profiles. Elucidating concurrent substance use 
patterns among adolescent stimulant users is crucial for identifying these subgroups 
and addressing their special needs. Adolescence underscores a critical period to 
develop substance use disorders (Kandel and Logan, 1984; Kosterman et al., 2000); 
thus strategies to curb nonmedical stimulant use and to further avoid other substance 






Table 1. Characteristics of past-year nonmedical ADHD stimulant users in a sample of the 
US adolescents aged 12-17(n=109,466): data from 2006–2011 National Survey on Drug 
Use and Health. 
Characteristics Nonmedical  ADHD stimulant use Comparison of 
groups 






    Male 











    12-13 
    14-15 














     Non-Hispanic White 
     Minorities 
 
1,727(80.7) 








     No 











     A,B, and C  











     < $20,000  
     $20,000- $49,999 
     $50,000- $74,999 

















     No 











     No 












     No 













Past-year SUD treatment 
     No 












     No 











     No 











     No 










*p<0.05, †p<0.01, ‡ p<0.001 
a. Adjusted model was adjusted for all variables included in this model. 
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Table 2. Characteristics of past-year nonmedical ADHD stimulant users, by concurrent 
problematic substance use class in a sample of the US population aged 12-17 (N= 




















    Male 














    12-13 
    14-15 
    16-17 
 
87 (11.1) 












44 (67.1)            
125 (68.5) 
Race 
    Non-Hispanic White 














    No 













Average Grade  
    A,B, and C  














    < $20,000  
    $20,000- $49,999 
    $50,000- $74,999 
    ≥ $75,000  
 
103 (12.4) 
















26 (11.1)             
62 (43.4) 
Past-year depression 
   No 














   No 















    No 



















    No 



















    No 



















   No 


















    No 















Table 3. Characteristics of past-year nonmedical ADHD stimulant users, by concurrent problematic substance use class in a sample of the US 
population aged 12-17 (N= 2,203): data from 2006–2011 National Survey on Drug Use and Health. 
Characteristics Prescription drug class 
  vs. Low substance class 
Alcohol/marijuana class 
 vs. Low substance class 
Multiple substance class 
 vs. Low substance class 
 OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) 
Gender 
   Male 




















   12-13 
   14-15 


























    Non-Hispanic White 




















    No 



















Average Grade  
    A,B, and C  




















    < $20,000  
    $20,000- $49,999 
    $50,000- $74,999 
































    No 




















    No 




















health  treatment 





















*p<0.05, †p<0.01, ‡ p<0.001 
a. Adjusted model was adjusted for gender, age, race, school dropout, grades, and income for these variables. For mental health and deviant 
behaviors variables, adjusted model was adjusted for gender, age, race, school dropout, average grades, household income, and the measured 
variable itself. 
    Yes 3.18(2.20,4.60)‡ 2.81(1.88,4.22)‡ 1.36(1.02,1.83)* 1.49(1.12,1.98)† 2.32(1.52,3.53)‡ 2.80(1.77,4.11)‡ 
Past-year SUD 
treatment 
    No 





















    No 





















   No 


























    No 























Figure 1. Prevalence of problematic use of other substances in four classes of adolescents with past-year nonmedical 







Multiple substance users, 7.7%
Prescription drug users, 14.8%
Alcohol-marijuana users, 41.2%
























Chapter 4. Part B. Patterns of Concurrent Substance Use Among Adult  
Nonmedical ADHD Stimulant Users 
Abstract 
Aims: To examine patterns of concurrent substance use among adults with 
nonmedical ADHD stimulant use.  
Methods: We used latent class analysis (LCA) to examine patterns of past-year 
problematic substance use (met any criteria for abuse or dependence) in a sample of 
6,103 adult participants from the National Surveys on Drug Use and Health 2006-
2011 who reported past-year nonmedical use of ADHD stimulants. Multivariate 
latent regression was used to assess the association of socio-demographic, mental 
health and deviant behavior characteristics with the latent classes.  
Results: A four-class model had the best model fit: 1) a class of participants with low 
probabilities for any problematic substance use (Low substance class, 53.3%); 2) 
problematic users of all types of prescription drugs (Prescription drug class, 13.3%); 
3) participants with high probabilities of problematic alcohol and marijuana use 
(Alcohol/Marijuana class, 28.8%); and 4) those with high probabilities of 
problematic use involving multiple drugs and alcohol (Multiple substance class, 
4.6%). Regression analyses indicated that a) participants in the 4 classes had distinct 
socio-demographic, mental health and service use profiles; b) individuals in the 
Multiple substance class were more likely to report mental health problems, deviant 
behaviors, and service use.  
Conclusion: Nonmedical users of prescription stimulants are a heterogeneous group 
with a large subgroup rarely having any problematic use of other substances. These 
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subgroups have distinct patterns of mental health comorbidity, behavior problems 

























       Nonmedical use of prescription stimulants, especially stimulants commonly 
prescribed for treatment of ADHD, has received increased research attention in the 
past decade (McCabe et al., 2007a; McCabe et al., 2007b; McCabe et al., 2005; 
Safer, 2000; Safer et al., 1996; Teter et al., 2005; Teter et al., 2006; White et al., 
2006). These Attention Deficit Hyperactivity Disorder (ADHD) stimulants mainly 
include methylphenidate and mixed amphetamine salts (Olfson et al., 2003; Zito et 
al., 2003), both of which are classified as schedule II based on the Controlled 
Substances Act (CSA), indicating their high abuse potential (Drug Enforcement 
Administration, 2003a).   
Several U.S. epidemiological surveys have shown that nonmedical ADHD 
stimulant use is a growing problem especially among young adults (Johnston, 2003a; 
SAMHSA, 2009a). A Web survey using an undergraduate sample in the Midwest 
U.S. showed that 8.1% of participants reported lifetime nonmedical ADHD 
stimulants use and 5.4% reported nonmedical use in the prior year (Vetter et al., 
2008). Other college based studies have had similar results with lifetime prevalence 
as high as 6.9% to 8.3% and past-year prevalence ranging from 4.1% to 5.9% 
(McCabe et al., 2005; Teter et al., 2006). Interestingly, college enrollment is a 
prominent risk factor for ADHD stimulant misuse. Data from the Monitoring the 
Future (MTF) study and the National Survey on Drug Use and Health (NSDUH) 
have shown that college students are twice as likely to report nonmedical use of 
ADHD stimulants compared to their counterparts not attending college (Johnston, 
2003a; SAMHSA, 2009a). Most previous studies focus on young adults (McCabe et 
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al., 2006a; McCabe et al., 2005; SAMHSA, 2009a; Teter et al., 2005; Teter et al., 
2006; White et al., 2006), thus failing to offer a complete picture of users in the 
general population.   
Past research also provides compelling evidence that nonmedical use of 
ADHD stimulants is associated with high risk behaviors such as other substance use 
or deviant behaviors (McCabe, 2008; McCabe et al., 2005; SAMHSA, 2009a; Teter 
et al., 2005). A report based on the College Alcohol Study (CAS) showed that 
nonmedical ADHD stimulants users were 10 times more likely than their counterpart 
to report past-year marijuana use, 7 times more likely to report binge drinking, 20 
times for cocaine use, and 5 times for drunken driving (McCabe et al., 2005). 
Another self-administrative web survey in college-age youth also reported that 
nonmedical ADHD stimulants use was associated with higher occurrence of 
substance use, regardless of their motivation (Teter et al., 2005). Based on a NSDUH 
report, 90 percent of college students who used Adderall®  nonmedically reported 
past-month binge drinking, and more than half of them were heavy alcohol users 
(SAMHSA, 2009a). Another study using NSDUH data further revealed that 
nonmedical ADHD stimulants use was usually preceded by other illegal substance 
use (Sweeney et al., 2013).  
While prior research indicates that nonmedical ADHD stimulant users have 
greater concurrent drug use or risky behaviors when compared with non-users 
(McCabe et al., 2007a; McCabe et al., 2005; McCabe and Teter, 2007; SAMHSA, 
2009a; Teter et al., 2005; Teter et al., 2006; White et al., 2006), it is unclear whether 
distinct subgroups of nonmedical ADHD stimulant users can be identified based on 
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their concurrent drug use patterns. Past research suggests that the motives for 
nonmedical ADHD stimulant use are varied, ranging from cognitive enhancement 
and scholastic study aid to recreational use, suggesting the heterogeneity of this 
population (Teter et al., 2005; White et al., 2006). It is therefore important to know 
whether or not these variations are reflected in the patterns of concurrent substance 
use. The delineation of these subgroups has implications for prevention and treatment 
of non-medical users of stimulants as concurrent use of substances are associated 
with more significant physical and psychological consequences compared to single 
substance use (Conway et al., 2003; Kandel et al., 2001; Tittle et al., 2003). For 
example, concurrent alcohol and cocaine users have a higher odds for the occurrence 
of past-year sexually transmitted diseases (STDs) and incarceration relative to single 
drug users (Hedden et al., 2009).   
In this study, we aimed to first identify the heterogeneous subgroups among 
nonmedical ADHD stimulant users by examining their concurrent problematic 
substance use patterns (defined as having any criteria for abuse or dependence), 
including alcohol and illegal drugs, using latent class analysis. Second, we examined 
the socio-demographic, psychological and social characteristics of these subgroups. 
We hypothesized that the class of nonmedical ADHD stimulant users with greater 
concurrent problematic substance use (i.e. high probabilities of multiple types of 
problematic substance use) would have more severe psychological problems, a 





2.1. Study sample and measures 
Combined annual data from the NSDUH public use data files for the years 
2006 to 2011 (N= 338,495) were analyzed. The study sample was restricted to adult 
participants aged 18 or older (N=229,029) who reported using ADHD medications 
nonmedically in the past year (N=6,103). The NSDUH is an annual cross-sectional 
survey sponsored by the Substance Abuse and Mental Health Administration 
(SAMHSA) and is designed to provide estimates of the prevalence of alcohol and 
drug use in the household population of the United States, 12 years of age and older. 
The survey employs a 50-state design with an independent multistage area 
probability sample for each of the 50 states and the District of Columbia. African-
American, Hispanic, and young populations are over-sampled to increase the 
precision of estimates for these groups. The response rate for household screening 
ranged from 87% to 91% and for completed interviews from 74% to 76% across the 
6 years. Survey items were administered by computer-assisted personal interviewing 
(CAPI) conducted by an interviewer and audio computer-assisted self-interviewing 
(ACASI). Use of ACASI was designed to provide participants with a highly private 
and confidential means of responding to questions and to increase the validity of 
reporting of illegal drug use and other sensitive behaviors. Participants were offered a 
$30 incentive payment for participation in the survey. Detailed information about the 
sampling and survey methodology of the NSDUH are found elsewhere (SAMHSA, 
2007, 2008, 2009, 2010, 2011, 2012).  
2.1.1. Assessment of past-year nonmedical ADHD stimulant use  
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       For the current analyses, ADHD stimulants are defined as stimulants with 
specific indications for treatment of ADHD, and included Ritalin®  or 
methylphenidate, Cylert® , Dexedrine® , Dextroamphetamine, Adderall® , and 
Vyvanse® . The survey used the following question to assess nonmedical use of any 
ADHD stimulants in the lifetime: “Have you ever, even once, used [Drug name] that 
was not prescribed for you or that you took only for the experience or feeling it 
caused?” Nonmedical ADHD stimulant use was defined as past-year if their time 
since last use was within the prior 12 months.  
2.1.2. Socio-demographic measures 
       Socio-demographic variables included in the analyses were gender, age (18-
25, ≥ 26), race/ethnicity (non-Hispanic white, race/ethnic minority), marital status 
(married, no longer married, never married), employment status (partial or full 
employment, unemployed, not in the labor force), education (less than high school, 
high school, college and above), annual household income (≤ $19,999, $20,000-
$34,999, $35,000-$69,999, ≥ $70,000).  
2.1.3. Past-year problematic substances use measures 
In order to reflect the spirit of DSM-5 (Harris and Edlund, 2005) that 
substance use disorders are dimensional instead of categorical disorders, we chose 
problematic substance use as the observed variables to identify the subgroups of 
nonmedical ADHD stimulant users. Past-year problematic substance use was defined 
by fulfilling any criteria for past-year substance abuse or dependence based on the 
Diagnostic and Statistical Manual of Mental Disorders–IV (DSM-IV) criteria 
(American Psychiatric Association, 1994). Substance abuse criteria included role 
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interference, hazardous use, problems with the law, and relationship problems. 
Substance dependence criteria included tolerance, withdrawal, taking larger amounts 
of substances or taking them for longer periods than intended, inability to cut down, 
time spent using the substance, giving up activities, and continued use despite 
substance-related problems in the past year. The substances examined included 
alcohol, marijuana, cocaine, heroin, hallucinogens, inhalants, and prescription 
opioids, and tranquilizers/sedatives (combined). If the participants answered 
positively to any criteria of abuse or dependence for these substances and specified 
their recent use in the past 12 months, they were categorized as past-year problematic 
users.  
2.1.4. Past-year mental health and deviant behavior variables 
Mental health variables included were past-year anxiety disorder and major 
depressive disorder (MDD), and serious psychological distress (SPD). MDD and 
anxiety disorder were assessed by participants’ self-report of past-year diagnosis by a 
medical doctor or health care professional. SPD was measured using the K6 
screening instrument for nonspecific psychological distress. For all survey years, 
participants were classified with past-year SPD if a score based on these K6 
measures was 13 or greater (Kessler et al., 2003). Past-year mental health and 
substance abuse service use were ascertained by asking participants whether they 
received any mental health treatment or substance abuse treatment in the past year. 
Past-year deviant behaviors were assessed by asking the participants how many times 
they had attacked someone with the intent to seriously hurting them, how many times 
they had sold illegal drugs, and how many times they had stolen or tried to steal 
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anything worth more than $50. Consistent with past research (APA, 2013; 
SAMHSA., 2009), participants who reported any of the four behaviors were 
categorized as having “deviant behavior” (0 for none of these behaviors and 1 for 
engaging in one of more of these behaviors at least once). Past-year incarceration 
was assessed by asking the participants how many times in the past 12 months they 
had been arrested and charged with breaking the law without counting minor traffic 
violations (0 for none and 1 for at least once). Past-year sexually transmitted disease 
(STD) was also assessed by participant self-reports of diagnosis by a medical doctor 
or health care professional. 
2.2. Statistical analyses 
       Complex latent class analysis (LCA) was used to identify subgroups 
according to concurrent problematic substance use among individuals who used 
ADHD stimulants in the past year. We performed LCA for 1 to 7 classes in order to 
ascertain the model with the optimal fit. Minimum values of the Bayesian 
Information Criterion (BIC) was given priority over other fit statistics such as 
Akaikes Information Criterion (AIC) and Sample Size Adjusted BIC (ABIC), given 
its more stable performance in simulation studies (Greenhill et al., 2002). We also 
considered the class size and clinical interpretability in selecting a model that would 
be applicable to the subsequent analysis of external validators.  
        LCA was applied using the Mplus software (Muthén, 2007). We chose eight 
dichotomous substance use variables (past-year problematic use of alcohol, 
marijuana, cocaine, heroin, hallucinogens, inhalants, and prescription opioid use, and 
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tranquilizers/sedatives) to empirically determine the smallest number of subtypes 
(classes) with similar drug use patterns that explain their response patterns.  
Once the number of classes was ascertained, correlates including socio-
demographics, mental health and deviant behaviors were incorporated into the 
models using unadjusted and adjusted multinomial regression models. These 
analyses were conducted using both a modal assignment latent regression approach 
with Stata 13.0 software (StataCorp, 2013), and the newly introduced Mplus three 
step (R3Step) latent regression model (Asparouhov T, 2012). As the results of the 
two sets of analyses were consistent and some of the ORs obtained from the 3-step 
latent regression model were extremely large due to its instability in survey design, 
here we only present results from modal assignment model. All analyses included 
adjustment for the complex survey design by taking into account the survey weights, 
clustering and stratification. All the percentages reported are weighted. A p<0.05 was 
used to ascertain the statistical significance of findings.  
 
3. Results 
3.1. Characteristics of the nonmedical ADHD stimulant users (Table 1) 
       The frequency distribution of participant characteristics is presented in Table 
1. Approximately 1.1% (n = 6,103) of adult participants from the NSDUH reported 
nonmedical use of ADHD stimulants in the past year. A relatively higher percent of 
nonmedical ADHD stimulant use was found among males (56.8%), young adults 
aged 18-25 (65.7%), whites (86.5%), those who had never married (79.0%), 
participants with some college experience or higher educational level (63.6%) and 
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with a household income < $20,000 (33.2%). Our adjusted logistic regression 
analyses further showed that they were more likely to report depression (aOR=1.25, 
95%CI [1.02,1.53]), anxiety disorder (aOR=1.25, 95%CI [1.01,1.56]), serious 
psychological distress (aOR=1.55, 95%CI [1.40,1.72]), to have received mental 
health treatment (aOR=1.22, 95%CI [1.02,1.46]) and SUD treatment (aOR=2.27, 
95%CI [1.84,2.81]), to report deviant behaviors (aOR=4.65, 95%CI [4.05,5.34]), 
incarceration (aOR=1.59, 95%CI [1.34,1.90]), and sexually transmitted disease 
(aOR=1.95, 95%CI [1.43,2.66]) in the past year.  
3.2. Subtypes of nonmedical ADHD stimulant users by LCA (Figure 1) 
       The greatest proportion of problematic substance use among nonmedical 
ADHD stimulants users involved alcohol (64.2%), followed by marijuana (43.6%), 
cocaine (10.6%), tranquilizers and sedatives (8.8%), hallucinogens (8.4%), heroin 
(2.5%), inhalants (2.3%), and pain relievers (2.1%).  
        Latent class analysis was performed for 1 to 7 class models. The fit statistics 
of AIC (13942.5), BIC (14141.9) and ABIC (14030.7) were lower for the 4-class 
compared to the 3-class model (AIC=14018.1; BIC=14166.3; ABIC=14083.7) and 
similar to or lower to the 5-class model (AIC=13918.4; BIC=14169.1; 
ABIC=14029.3), suggesting that the minimum fit index values were obtained for the 
4-class model (Greenhill et al., 2002). Whereas the Vuong-Lo-Mendel-Rubin 
(VLMR) test results supported a 2-class model, indicating a better fit (2-class: 
p=<0.0001; 3-class: p=0.2135). By taking into account the minimum value of BIC as 
well as the clinical interpretability, a 4-class model was selected (Appendix Table 3).        
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       Figure 1 plots the past-year nonmedical ADHD stimulant use on the x-axis 
and the probability of past-year problematic use with each substance for the four 
classes as indicated on the y-axis. Class 1, which was the largest class and comprised 
53.3% of the sample, was comprised of individuals with moderate probabilities of 
problematic use of alcohol (53.5%) and marijuana (21.6%) and near zero 
probabilities of other problematic substance use (class 1 - Low substance class, 
53.3%). Class 2 made up 13.3% of the study sample and also consisted of individuals 
with moderate probabilities of problematic use of alcohol and marijuana, but 
additionally included participants with high probabilities of problematic use of pain 
relievers and sedatives/tranquilizers (class 2 - Prescription drug class, 13.3%). Class 
3 included individuals with remarkably high probabilities of problematic use of 
marijuana and alcohol (class 3 – Alcohol/marijuana class, 28.8%). Finally, class 4 
was comprised of individuals who had high probabilities of problematic use of most 
of the substances examined (class 4 - Multiple substance class, 4.6%). 
3.3 Characteristic of participants in the LCA-defined classes (Table 2 and 3) 
       Table 2 presents the socio-demographic, mental health and deviant behavior 
profiles of the 4 classes of past-year nonmedical ADHD stimulant users. Prescription 
drug and Multiple substance classes showed particularly high prevalence of mental 
health problems such as major depression (Prescription drug: 30.6%; Multiple 
substance: 28.3%), anxiety disorder (Prescription drug: 28.2%; Multiple substance: 
24.0%), serious psychological distress (Prescription drug: 52.4%; Multiple 
substance: 53.6%). Multiple substance class had exceptionally high prevalence of 
deviant behaviors (79.3%) and incarceration (33.3%). Results from the unadjusted 
83 
 
and adjusted latent regression models are presented in Table 3 which presents the 
odds ratios (ORs) and adjusted odds ratios (aORs) with class 1 (Low substance class) 
as the reference class. Relative to the Low substance class, being unemployed was 
associated with a greater odds of being in all of the other classes, while having some 
college education or higher (vs. less than high school education), being female, and 
being in the ≥ 26 years age class (vs. being in age class <26 years) were associated 
with lower odds of being in the Alcohol/marijuana class and Multiple substance 
class. Additionally, Prescription drug class participants were more likely to be older 
and no longer married relative to the Low substance class, which showed distinct 
profiles compared to Alcohol/marijuana and Multiple substance classes.  
       Compared with the Low substance class, unadjusted models showed that both 
the Prescription drug and Multiple substance classes were more likely to have 
psychiatric problems (major depression, anxiety disorder, serious psychological 
distress), to have a history of service use (mental health or substance service use) and 
to report deviant behaviors and incarceration. However, the Alcohol/marijuana class 
only had higher odds of past-year serious psychological distress, substance service 
use, deviant behaviors and incarceration compared to Low substance class. 
Nevertheless, with few exceptions, participants in class 2-4 were overall more likely 
to have all types of mental health problems, mental health and substance service use, 
deviant behaviors and incarceration even after adjusted for socio-demographics. The 
Multiple substance class additionally had higher odds of past-year sexually 





        To our knowledge, this is the first study to examine concurrent problematic 
substance use patterns among adults who reported nonmedical ADHD stimulant use 
in a nationally representative sample. There are three main findings in this study. 
First, there exists a large subgroup (Low substance class) among the nonmedical 
ADHD stimulants users that simply had problematic moderate alcohol and marijuana 
use, which has not been reported in prior literature. Second, the other three subgroups 
including Prescription drug class, Alcohol/marijuana class and Multiple substance 
class all had high probabilities for mental health problems, service use, and deviant 
behaviors relative to the Low substance class. Third, participants in the 4 classes had 
distinct socio-demographic, mental health and service use profiles.   
       Consistent with previous literature, nonmedical ADHD stimulant users were 
more likely to report other substance use and risky behaviors compared to non-users 
(Arria et al., 2008; Herman-Stahl et al., 2007; McCabe et al., 2005; McCabe and 
Teter, 2007; Teter et al., 2005; Teter et al., 2006; White et al., 2006). Epidemiologic 
studies have found relationships between nonmedical use of prescription stimulants 
and presence of depressed mood among youth (Compton et al., 2006; Poulin, 2007; 
Teter et al., 2010). It is noteworthy that our study further found these users were 
more likely to have clinician-identified depression and anxiety and self-reported 
serious psychological distress with prior mental health treatment, even after 
adjustment for socio-demographic characteristics. It is possible that the stimulant 
users developed psychological problems after using the stimulants or used these 
drugs for self-medication (Khantzian, 1997). A previous study suggested that 39% of 
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college prescription stimulant use was for self-treatment (McCabe et al., 2009). Our 
finding underscores the significance of screening for mental health disorders among 
the nonmedical ADHD stimulant users. 
       Our study further documents the presence of considerable heterogeneity 
among nonmedical ADHD stimulant users. More than half of the nonmedical ADHD 
stimulant users comprised the Low substance class, which has the lowest prevalence 
of mental health problems and risky behaviors in the class of non-medical stimulant 
users. However, a large proportion (53%) of individuals in the Low substance class 
reported problematic alcohol use and 21.6% reported problematic marijuana use. 
This finding is consistent with a previous report also based on the NSDUH data 
indicating that college students who used Adderall®  nonmedically were 3 times 
more likely to drink heavily and twice as likely to binge drink compared to nonusers 
(SAMHSA, 2009a). In view of the adverse physical, mental and social consequences 
of problematic alcohol use (Brown et al., 2000; Chesson et al., 2000; Hingson et al., 
2009), greater attention to alcohol-related problems among this subgroup is needed.  
       Consistent with our hypothesis, Prescription drug, Alcohol/marijuana and 
Multiple substance classes were all more likely to report mental health problems, 
mental and substance abuse service use, and deviant behaviors compared to Low 
substance class. Furthermore, the three classes were all less likely to have college or 
higher education and were more likely to be unemployed compared to the Low 
substance class, indicating their relatively lower socio-economic status and fewer 
resources. These individuals are probably in greater need of both substance and 
mental health services as previous studies have shown that individuals with more 
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severe substance comorbidity tend to have greater unmet need for professional care 
(Chen et al., 2013; Wang et al., 2005). 
       The socio-demographic characteristics of the three classes with a greater 
number of concurrent problematic substance use differed. Whereas the 
Alcohol/marijuana and Multiple substance class were more likely to be younger, 
male and never married, the Prescription drug class were more likely to be older and 
no longer married. Past research has also found that individuals with tranquilizer or 
sedative abuse or dependence are generally middle-aged or older (Becker et al., 
2008). In addition, the odds of having psychiatric comorbidity and service use in the 
Alcohol/marijuana class were much lower than those in Prescription drug classes; 
however, these two classes did not show remarkably different odds of having deviant 
behaviors and incarceration. This finding implies that the Alcohol/marijuana class 
may simply have high impulsivity but not a greater burden of mental health 
problems. In contrast, the Prescription drug class had a high probability of all mental 
disorders examined (depression: 30.6%, anxiety: 28.2%, serious psychological 
distress: 52.4%), which may be explained by the nonmedical use of opioids or 
tranquilizers/sedatives taken to self-medications for psychiatric symptoms (Becker et 
al., 2008; Joranson et al., 2000; Kreek and Koob, 1998).  
      Compared to the Low substance class, the Multiple substance class 
participants were significantly more likely to report mental health problems, mental 
and substance service use, behavior problems, and sexually transmitted diseases. 
Previous studies have shown that comorbid substance use and psychiatric disorders 
confer an additional risk for poorer outcomes and treatment response among opioid-
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abusing patients (Strain, 2002; Volkow et al., 2002). Similarly, the use of alcohol in 
combination with other drugs is associated with more severe psychological and social 
consequences (Hasin et al., 2007; Hedden et al., 2009). A previous study pointed out 
that substance comorbidity is associated not only with greater odds of service use but 
also with higher perceived unmet service needs (Chen et al., 2013), indicating that 
more clinical resources should be available to this population. 
       This study has several strengths, including a large sample size and 
generalizability to the US household population. However, our findings should be 
interpreted in light of several limitations, mainly inherent to the NSDUH. First, the 
cross-sectional survey data limits assessment of temporal relationships and causal 
inferences. Second, two of the mental health measures (e.g. clinician-identified 
depression and anxiety) were subject to health care utilization. Third, we were not 
able to explore the motives and the trajectories of substance use which may offer 
significant implications for prevention. Lastly, all the information were based on self-
report, which is vulnerable to recall and reporting biases, particularly for data on 
substance use and other sensitive behaviors. However, the validity of substance use 
has been established in a previous study (Harrison, 2007). 
 
5. Conclusion      
       Our study provides evidence for 1) the existence of distinct subgroups of 
problematic substance users among adult nonmedical ADHD stimulant users; and 2) 
differences in the socio-demographic, health and behavioral profiles of these 
subgroups. Thus, differentiating concurrent substance use patterns among the users is 
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important for clinicians and public health policy makers. More than half of the users 
constitute the Low substance class, who while at risk for alcohol-related problems, 
are not at increased risk for using “hard drugs” or experiencing adverse health and 
social outcomes. The study also identified a Multiple substance class, which is a 
population that is in need of more resources due to larger number of problematic use 
of substances and higher severity of psychosocial consequences. Future studies 
which explore potential variations in sources of nonmedically used stimulants and the 
reasons for use of these drugs among these subgroups of stimulant users would 







Table 1. Characteristics of past-year nonmedical ADHD stimulant users in a 
sample of the US population aged 18 and above (N= 6,103): data from 2006–2011 
National Survey on Drug Use and Health. 







   Male 
   Female 
   
3,369(56.8)         





    18-25 
    ≥ 26 
 
5,347(65.7)           





    Non-Hispanic White 
    Minorities 
       






    Married 
    No longer married 
    Never married  
 
372(12.6)       







    Full/Partial 
    Unemployed  
Not labor force 
 
4,136(69.8)          







    < high school 
    High school 
    ≥ College  
   
794(11.2)         
  1,648(25.2)        






    < $20,000  
    $20,000- $49,999 
    $50,000- $74,999 
    ≥ $75,000  
   
2,425(33.2)         
 1,650(29.1)         
 738(12.9)        







    No 
    Yes 
   
5,160(84.8)         





    No 
    Yes 
 







    No 
    Yes 
 
 
4,345(70.8)        





Past-year mental health 
treatment 
    No 
    Yes 
 
4,743(75.8)        




Past-year SUD treatment 







    Yes         581(10.1) 2.27(1.84,2.81)‡ 
Past-year deviant behavior 
    No 
    Yes 
 






    No 
    Yes 
 
5,152(86.3) 





    No 
    Yes 
 
5,891(95.9) 























Table 2. Characteristics of past-year nonmedical ADHD stimulant classes identified 
through latent class analysis in a sample of the US population aged 18 and above 













Total 2,995(53.3) 718(13.3) 2,064(28.8) 326(4.6) 
Gender 
   Male 
   Female 
   
1,556(54.6)         
 1,439(45.4) 
 
349(51.5)       
    369(48.5) 
 
1,271(62.4)        
   793(37.6) 
 
193(63.7)        
   133(36.3) 
Age 
    18-25 
    ≥ 26 
 
2,578(61.0)           
417(39.1)          
 
558(50.1)           
160(49.9)         
 
1,912(80.1)         
152(19.9)      
   
299(75.6)        
27(24.5)      
Race 
    Non-Hispanic White 
    Minorities 
      
  2533(86.4) 
462(13.6) 
 









    Married 
    No longer married 
    Never married  
 
225(15.9)       
    107(8.3)          
2663(75.9) 
 
73(18.4)       
62(17.7)          
583(63.9) 
   
66(5.0)       
  46(4.4)         
  1952(90.6) 
 
8(6.4)          
  14(6.7)          
304(86.9) 
Employment 
    Full/Partial 
    Unemployed  
Not labor force 
 
2116(72.8)          
 214(7.6)       
    665(19.7) 
 
459(65.7)        
 100(12.4)         
  159(21.9) 
 
1376(67.9)       
249(11.2)          
439(21.0) 
   
185(59.1)       
79(20.8)         
  62(20.2)   
Education 
    < high school 
    High school 
    ≥ College  
   
271(8.8)         
  645(19.7)        
  2079(71.5) 
 
156(16.2)        
238(33.8)        
   324(50.0) 
 
282(11.6)       
622(27.9)       
  1160(60.6) 
 
85(20.9)         
 143(47.6)        
   98(31.6) 
Income 
    < $20,000  
    $20,000- $49,999 
    $50,000- $74,999 
    ≥ $75,000  
   
1198(32.2)         
 763(26.9)         
 368(13.6)        
  666(27.3) 
 
240(27.4)        
249(39.3)      
  92(10.8)       
   173(22.5) 
 
866(37.4)         
 547(28.5)          
235(12.8)         
 416(21.3) 
 
121(35.6)        
91(29.9)         
43(11.0)         
 71(23.5) 
Past-year Depression 
    No 
    Yes 
   
2658(88.2)         
  299(11.8) 
   
502(69.4)          
  205(30.6) 
 
1778(87.6)          
  249(12.4) 
 
222(71.7)        
   99(28.3) 
Past-year Anxiety 
    No 
    Yes 
 
2749(91.6)     
      246(8.5) 
 
532(71.8)         
  186(28.2) 
   
1853(89.8)       
    211(10.2) 
 




    No 
    Yes 
 
 
2372(78.2)        
   623(21.8) 
 
 
367(47.6)         
  351(52.4) 
 
 
1448(71.6)         
  616(28.4) 
 
 
158(46.4)         
  168(53.6) 
Past-year mental health 
treatment 
    No 
    Yes 
 
 
2483(81.6)        
   502(18.4)    
 
 
417(52.9)         
  296(47.1) 
 
 
1640(78.0)      
    418(22.0) 
 
 
203(59.9)       
    120(40.1) 
Past-year SUD treatment     
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    No 
    Yes 
2866(95.2)  
      129(4.8) 
573(74.5)         
  145(25.5) 
1852(90.3)        
   212(9.7) 
231(70.9)       
    95(29.1) 
Past-year deviant 
behavior 
    No 
    Yes 
 
2497(84.6)      
498(15.4) 
 
400(63.3)          
 318(36.7) 
 
1103(56.9)       
    961(43.1) 
 
65(20.7)         
261(79.3) 
Past-year Incarceration 
    No 
    Yes 
 
2715(90.6) 
      280(9.4) 
 
555(80.2)        
   163(19.8)   
   
1681(84.2)        
   383(15.8)   
 
201(66.7)       
    125(33.3) 
Past-year STD 
    No 
    Yes 
 
2905(95.7)        
90(4.3) 
 
689(97.0)        
   29(3.0) 
 
1993(96.5)        
   71(3.5) 
 
304(90.4)       
    22(9.6) 
*p<0.05, †p<0.01, ‡ p<0.001 
a. Adjusted model was adjusted for all variables included in this table. 
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Table 3. Comparison of classes of past-year nonmedical ADHD stimulant users identified through latent class analysis in a sample of the US 
population aged 18 and above (N= 6,103): data from 2006–2011 National Survey on Drug Use and Health. 
Characteristics Prescription drug class 
v.s Low substance class 
Alcohol/marijuana class 
v.s Low substance class 
Multiple substance class  
v.s Low substance class 
 OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) 
Gender 
   Male 




















    18-25 




















    Non-Hispanic White 




















    Married 
    No longer married 


























    Full/Partial 
    Unemployed  


























    < high school 
    High school 


























    < $20,000  
    $20,000- $49,999 
    $50,000- $74,999 


































   No 




















   No 





















   No 

























Past-year mental health 
treatment 
   No 



























   No 



























   No 


























   No 




















   No 



















a. Adjusted model was adjusted for gender, age, race, marital status, employment, education, and income for these variables. For 
mental health and deviant behaviors variables, adjusted model was adjusted for gender, age, race, marital status, employment, 




Figure 1. Conditional probabilities of problematic use of substances among 6,103 participants of 2006–2011 National 







Multiple substance class, 4.6%
Alcohol-marijuana class, 28.8%
Prescription drug class, 13.3%
























Chapter 5: Discussion 
      This chapter will first present an overview of the key findings of each of the 
three studies. Study limitations and strengths will next be described, followed by a 
discussion of public health implications, and finally concluding remarks.    
5.1. Overview of Main Findings  
5.1.1. Aim 1 (Chapter 2)  
       The study described in Chapter 2 investigated the temporal trends of 
treatment visits, nonmedical use of, and ED visits for Adderall and methylphenidate 
among adults and adolescents from 2006 to 2011. The relationship between treatment 
visits, nonmedical use and ED visits were also examined using OLS regression 
model. While previous studies have implied the possibility that increased nonmedical 
ADHD stimulants use resulted from the increased availability (e.g. prescription) of 
ADHD stimulants (Cohen et al., 2006; McCabe and Boyd, 2005), our study showed 
that trends in treatment visits for stimulants did not correspond to trends of 
nonmedical use of these drugs. For instance, nonmedical Adderall use grew 
remarkably among adults while Adderall treatment visits remained stable. In 
addition, although friends or relatives were the major source of nonmedically used 
stimulants, up to two-thirds of these friends or relatives obtained their medications 
through legitimate prescriptions from physicians, regardless of age groups. These 
results suggest that increased drug diversion instead of increased availability may 
play a role in the increased trend of nonmedical ADHD use among adults. This study 
also found that adult ED visits involving Adderall was strongly correlated with 
increased nonmedical use in adults, suggesting the adverse health consequences tied 
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to nonmedical use. The findings of this study underscore the importance of 
preventive strategies to target at possible drug diversion trajectories as well as the 
urgent need of public health campaign to educate stimulant users regarding the 
physical hazards of these drugs.     
5.1.2. Aim 2 (Chapter 3)  
     The study described in Chapter 3 aimed to examine the role of source of 
misused stimulants in nonmedical use of prescription stimulants. Previous studies 
have found that a friend or relative was the major source for the nonmedically used 
prescription stimulants (DeSantis and Hane, 2010; Garnier-Dykstra et al., 2012; 
McCabe et al., 2006b; White et al., 2006). This study further used medication source 
as a predictor to characterize the socio-demographics, psychological and behavioral 
profiles of nonmedical prescription stimulant users. In addition, the relationship 
between sources and the onset, recency, severity of stimulant use was examined. 
Consistent with previous studies, the most common source of these stimulants was a 
friend and relative, followed by physician source and illegal source. The results 
found that participants reporting different sources had different risk profiles: those of 
physician source had higher mental health burden while those of illegal source 
reported more behavioral problems. Physician source group had high odds of 
reporting early onset, recent use, frequent use and stimulant use disorders while 
illegal source group reported only early onset, frequent use and stimulant use 
disorders. Future efforts should be made to assure physicians to be equipped with 
sufficient training to identify these nonmedical users, the possible diversion 
behaviors, and high comorbid mental health problems. Illegal source group who had 
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lower socio-economic status and higher behavioral problems should be allocated 
with more clinical and social resources.  
5.1.3. Aim 3 (Chapter 4)  
The study described in Chapter 4 aimed to use latent class analysis (LCA) to 
identify heterogeneous subgroups of past-year nonmedical use of ADHD stimulant 
users by their concurrent problematic substance use. 2006-2011 NSDUH was used 
and subgroup analysis (adolescents v.s. adults) was also performed. Among adults, a 
four class model had the best model fit. These included Low substance class (53.3%), 
Prescription drug class (13.3%), Alcohol/Marijuana class (28.8%), and Multiple 
substance class (4.6%). Regression results showed that adult participants in the 
Prescription drug class and Multiple substance class had higher mental health 
burden and behavior problems than Low substance class while those in the 
Alcohol/Marijuana class only showed higher behavior problems. Among 
adolescents, a four class model was chosen, which included Low substance class 
(30.7%), Prescription drug class (16.9%), Alcohol/Marijuana class (44.1%), and 
Multiple substance class (8.3%). Regression results showed that compared to Low 
substance class, adolescent participants in other three classes all showed higher odds 
of major depression and behavior problems. This is the first study to show that 
nonmedical prescription stimulant users are a heterogeneous group with a large 
subgroup rarely having any problematic use of other substances. These subgroups 
have distinct patterns of mental health comorbidity, behavior problems and service 
use, with implications for prevention and treatment of nonmedical stimulant use, 
which also differed in different age groups. The findings can offer implications to 
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develop a more targeted preventive strategy for clinicians and policy makers to curb 
prescription stimulant misuse.     
 
5.2. Study Limitations  
These findings should be interpreted in light of several limitations. First, we 
utilized NSDUH from aim 1 to aim 3, which has brought inherent limitations the 
three studies. NSDUH is a cross-sectional survey dataset, limiting further assessment 
of temporal relationship and causal inference of nonmedical prescription stimulant 
use and other psychiatric or behavior problems examined. Also, all the information in 
NSDUH was based on self-report, which is open to social-desirability or recall bias. 
In addition, NSDUH is a household representative surveys which may fail to capture 
the homeless and jailed population, which were known to have even higher 
prevalence of substance use disorders (Department of Housing and Urban 
Development, 2011; Peters et al., 1998).  Another limitation of this study lies in the 
limited available survey years in NSDUH data: questions regarding nonmedical use 
of Adderall were not added until year 2006. The available years so far (2006-2010) 
may not provide enough data for trend analysis, although we plan to add future 
survey years as they become available.  
In the aim 1 study, we used three national representative surveys (NDTI, 
NSDUH, and DAWN) which were not linked to each other. Thus, the interpretation 
of the findings should be viewed in an ecological perspective. For example, we found 
that an increased trend of nonmedical Adderall use and that of ED visits involving 
Adderall among adults. However, we were not able to assess if those who visited ED 
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received Adderall through a physician’s prescription. Also, any shifts in medical care 
policy or in drug market share which might impact the treatment visits of specific 
stimulants cannot be captured by these data. Additionally, treatment visits for 
methylphenidate and Adderall cannot directly represent the availability of these 
medications since the information of other sources cannot be obtained. Lastly, both 
NDTI and DAWN rely on physicians’ reports, which may be vulnerable to recall 
bias.    
The NSDUH was used in the aim 2 study; thus, there existed other limitations 
in addition to above-mentioned ones. For instance, the NSDUH asks for the most 
recent source of misused stimulant instead of most commonly used, which may not 
be the same. Also, this study could not capture those who reported multiple sources 
of these stimulants. Another limitation is that those who used Adderall only were not 
asked regarding their sources due to Adderall was added to the NSDUH 
questionnaire later on. Last, given the cross-sectional nature of the NSDUH, causal-
relationship of nonmedical stimulant use and other psychiatric or stimulant use 
problems is hard to be established. 
The major limitations lying in aim 3 study were tied to NSDUH design. Thus, 
cross-sectional survey as well as self-report bias was the major limitation. However, 
it should be noted that the mental health measures (e.g. clinician-identified 
depression and anxiety) examined in this study were subject to health care utilization, 
which cannot be generalized to the population without medical coverage. Also, the 
motives and the trajectories of nonmedical prescription stimulant use and other 
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mental or substance use were unknown, which may offer significant implications for 
prevention.  
 
5.3. Study Strengths  
Offsetting the aforementioned limitations are several strengths. First, 
NSDUH, used in all three aims, has the advantage of a large sample size and 
generalizability to the US household population. Similarly, the other datasets such as 
DAWN, NDTI, and NSCH all have such strengths. Second, this study attempts to 
examine the role of prescriptions in nonmedical use of prescription stimulants by 
conducting the trend analysis (aim 1) and the source of misused stimulants (aim 2), 
which can offer different perspectives of this issue. Third, that this study conducted 
subgroup analysis for adolescents (aged 12-17) and adults (aged 18 and above) while 
most of previous studies focus on college age population (McCabe et al., 2005; 
McCabe et al., 2006b; SAMHSA, 2009a; Teter et al., 2005; Teter et al., 2006) or 
adolescents (Herman-Stahl et al., 2007; Johnston, 2003; McCabe et al., 2007a). 
Fourth, this study, to my knowledge, is also the first to report state-level estimates of 
nonmedical prescription stimulant use. Fifth, this is also the first study to explore the 
heterogeneity of subgroups of nonmedical prescription stimulant users by concurrent 
substance use, which provides a unique opportunity to develop a more targeted 
preventive strategy to curb the misuse of these stimulants. Together, this study 
offered a comprehensive picture of nonmedical prescription stimulants including 
temporal trends, sources of medications, and users’ profiles and aimed to examined 
the role of prescriptions in nonmedical use, which can which could offer major 
102 
 
implications in our understanding of the etiology and possibly prevention of 
nonmedical ADHD stimulant use by health professionals and policy makers. 
  
5.4. Public Health Implications   
The three aims in this study can complement previous research and offer 
significant public health and clinical implications. There are mainly three possible 
strategies which could help in reducing the epidemics of nonmedical prescription 
stimulants use. The first one and the most important step, is to develop clinical and 
preventive program targeting at drug diversion. Given that our aim 1 study showed 
that physicians constituted two-thirds of the source of the misused stimulants and 
nonmedical Adderall use increased without the treatment visits increasing 
accordingly, drug diversion may be an important way for the nonmedical prescription 
stimulant users to obtain their drugs. Thus, there is an urgent need for public health 
campaigns to 1) educate the users and the dispensers about the legal responsibility of 
misusing or diverting the medications; 2) educate our physicians to increase their 
vigilance regarding possible diversion of these medications.  
Second, a more targeted preventive or treatment program should be 
developed. Our aim 1 and aim 3 both demonstrated that the temporal trends and 
users’ profiles of nonmedical prescription stimulant users differ in adolescents and 
adults. Our aim 3 further showed that the users consisted of very distinct subgroups 
with different substance and psychiatric comorbidities, with a large group (Low 
substance class) consuming minimal illegal substances other than prescription 
stimulants. This subgroup may well respond to a public health campaign which can 
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dilute the illusion that “use of prescription drugs is safe”. Meanwhile, the Multiple 
substance class (in aim 3) which have numerous problematic substance uses and 
carry more mental health burden, require more clinical resources, knowing that worse 
outcome or treatment response may be expected (Hasin et al., 2007a; Strain, 2002b; 
Volkow et al., 2002).  
Third, our aim 2 offers evidence that source of misused stimulants could be a 
significant indicator of stimulant use problems, including onset, frequency and 
severity.   Those who obtained medication from physicians carried more psychiatric 
risks and also had higher odds of poor indicators of stimulant use problems (e.g. 
early onset, recent use, and stimulant use disorder). Efforts should be made to 
develop a physician training program which helps to recognize the misuse and 
diversion among patients. In addition, since illegal source group had higher odds of 
risky behaviors and incarceration, efforts to curb stimulant misuse in this population 
should also criminal justice officials and government regulatory agencies to reduce 
the availability of these stimulants in the black market. A tailored preventive program 
should be developed taking into consideration of different sources of misused 
medications.  
 
5.5. Future directions 
Given the proven therapeutic efficacy of prescription stimulants for the 
treatment of ADHD (Goldman et al., 1998), there is a need to balance between the 
medical necessity of these drugs and the risks associated with nonmedical 
prescription stimulant use. Further research should be conducted to better understand 
104 
 
the trajectory of the nonmedical users, the pathway of diversions, and the impact of 
national or state-level policy. 
As my aim 1 study offers a recent temporal trend of nonmedical use of 
prescription stimulants for different stimulants among different population, a 
valuable next step will be repeated and regular evaluation of these trends especially 
after Prescription drug Abuse Prevention Plan was implemented in 2011 by the 
Obama Administration (The White House). Since my three aims focused on national 
data from 2006 to 2011, whether the problem of prescription stimulant misuse can be 
curbed after 2011 can be an indicator of the effectiveness of this prevention plan.  
Although my aim 2 illustrated the individuals obtained the misused stimulants 
via different sources had different psychiatric and behavioral risk profiles and 
different level of stimulant use problems. Efforts should be put to further understand 
the pathways of drug diversion from the dispensers’ side and the trajectory of 
nonmedical prescription stimulants from the users’ side. The following questions 
need to be answered: 1) What proportion of those who get legitimate prescriptions 
will divert their medications and what is the risk factor for them to divert the drugs? 
2)  How do drug dealers acquire their inventories of prescription stimulants from 
clinicians, hospitals/clinics, pharmacies and even patients? 3) When do the stimulant 
users develop other substance use or other mental health problems? A longitudinal 
study which can better delineate the causal relationship should be conducted, which 
could also help explain the heterogeneity of the nonmedical prescription stimulant 
users we demonstrated in aim 3. 
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Finally, the most important step involves efforts to dissemination of the 
findings to clinicians, educators, policy makers, and even general population, as 
discussed in the previous implication section. They included 1) public health 
campaigns to inform the general public about the risk of stimulant misuse; 2) 
education programs to encourage school teachers, clinicians, parents to be alert of 
possible drug diversion and to educate the drug diverters of their legal risks; 3) policy 
makers should be aware that there exist a group of nonmedical prescription stimulant 
users with other substance and mental problems who require more clinical resources. 
Thus, translating the research findings into practice is critical. 
 
5.6. Conclusions 
In summary, our three aims offer a global picture of nonmedical prescription 
stimulants in temporal trends, various sources, and users’ profiles. Although aim 1 
showed trends of nonmedical use does not correspond to the trends of treatment 
visits, aim 2 provided evidence that physician source group has poor outcome of 
stimulant use problems and higher psychiatric comorbidities. As physician is the 
major source of stimulants used nonmedically across age groups, drug diversion 
should be targeted as a preventive strategy. Aim 3 identified the heterogeneous 
subgroups existing in nonmedical prescription stimulant users, which calls for a more 
tailored preventive or treatment program. Thus, efforts should be made to bring the 
findings of this study into practice or policy and further in-depth research should be 






Table 1-1. Temporal trend of prescription, nonmedical use and emergency department (ED) 
visits of Adderall and methylphenidate using quarterly data in a community sample of the U.S. 
population aged 12 to 17. 
 Adderall  Methylphenidate 
Prescription  Nonmedical 
use  
ED visits  Prescription  Nonmedical 
use  
ED visits  
Coeffi
cient 
-9.240 -0.008 0.006 -3.47 -0.040 0.0059 
SE 1.570 0.010 0.022 0.68 0.006 0.0130 
F test 0.000 0.454 0.787 0.000 0.000 0.648 
Table 1-2. Temporal trend of prescription, nonmedical use and emergency department visits of 
Adderall and methylphenidate using quarterly data in a community sample of the U.S. 
population aged 18 and above. 
 Adderall  Methylphenidate 
Prescription  Nonmedical 
use  
ED visits  Prescription  Nonmedical 
use  
ED visits  
Coeffi
cient 
-1.220 0.023 0.024 0.134 0.002 0.002 
SE 1.580 0.004 0.003 1.330 0.003 0.001 
F test 0.450 0.000 0.000 0.921 0.557 0.244 





















































Table 2. Fit statistics of latent class analysis of nonmedical ADHD stimulant users based 
on concurrent problematic substance use for the 2-6 class models using a community 
sample of the U.S. population aged 12-17. 
Classes Entropy -2LL AIC BIC Adjusted 
BIC 
LMRa 
2 0.701 1260.570 14221.541 14318.400 14264.388 0.0000 
3 0.737 221.421 14018.120 14166.257 14083.651 0.0324 
4 0.650 93.587 13942.533 14141.948 14030.748 0.3284 
5 0.692 42.133 13918.400 14169.094 14029.299 0.6341 
6 0.659 35.449 13899.021 14200.993 14032.604 0.6233 
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Table 3. Fit statistics of latent class analysis of nonmedical ADHD stimulant users based 
on concurrent problematic substance use for the 2-5 class models using a community 
sample of the U.S. population aged 18 and above. 
Classes Entropy -2LL AIC BIC Adjusted 
BIC 
LMRa 
2 0.721 2073.411 33031.820 33146.002 33091.980 0.0000 
3 0.578 285.482 32764.339 32938.969 32856.348 0.2135 
4 0.576 254.720 32527.619 32762.697 32651.477 0.4344 
5 0.664 49.746 32495.873 32791.401 32651.581 0.5304 







































Anthony, J.C., Petronis, K.R., 1995. Early-onset drug use and risk of later drug 
problems. Drug and alcohol dependence 40, 9-15. 
American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental 
Disorders: 4th Ed. American Psychiatric Publishing. Washington, DC. 
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental 
Disorders: 5th Ed. American Psychiatric Publishing. Arlington,VA. 
Arria, A.M., 2008. Nonmedical Use of Prescription Stimulants and Analgesics: 
Associations with Social and Academic Behaviors among College Students. J Drug 
Issues 38, 1045-1060. 
Arria, A.M., Caldeira, K.M., O'Grady, K.E., Vincent, K.B., Johnson, E.P., Wish, 
E.D., 2008. Nonmedical use of prescription stimulants among college students: 
associations with attention-deficit-hyperactivity disorder and polydrug use. 
Pharmacotherapy 28, 156-169. 
Arria, A.M., DuPont, R.L., 2010. Nonmedical prescription stimulant use among 
college students: why we need to do something and what we need to do. J Addict Dis 
29, 417-426. 
Arria, A.M., Wish, E.D., 2006. Nonmedical use of prescription stimulants among 
students. Pediatr Ann 35, 565-571. 
Asparouhov T, M.B., 2012. Auxiliary variables in mixture modeling: A 3-step 
approach using Mplus. 
Babcock, Q., Byrne, T., 2000. Student perceptions of methylphenidate abuse at a 
public liberal arts college. J Am Coll Health 49, 143-145. 
110 
 
Barrett, S.P., Darredeau, C., Pihl, R.O., 2006. Patterns of simultaneous polysubstance 
use in drug using university students. Hum Psychopharmacol 21, 255-263. 
Blanco, C., Alderson, D., Ogburn, E., Grant, B.F., Nunes, E.V., Hatzenbuehler, M.L., 
Hasin, D.S., 2007. Changes in the prevalence of non-medical prescription drug use 
and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug 
Alcohol Depend 90, 252-260. 
Boyd, C.J., McCabe, S.E., Cranford, J.A., Young, A., 2006. Adolescents' motivations 
to abuse prescription medications. Pediatrics 118, 2472-2480. 
Boyd, C.J., McCabe, S.E., Cranford, J.A., Young, A., 2007. Prescription drug abuse 
and diversion among adolescents in a southeast Michigan school district. Arch 
Pediatr Adolesc Med 161, 276-281. 
Chakraborty, K., Grover, S., 2011a. Methylphenidate-induced mania-like symptoms. 
Indian J Pharmacol 43, 80-81. 
Chakraborty, K., Grover, S., 2011b. Methylphenidate-induced mania-like symptoms. 
Indian J Pharmacol 43, 80-81. 
Chen, L.Y., Crum, R.M., Martins, S.S., Kaufmann, C.N., Strain, E.C., Mojtabai, R., 
2013. Service use and barriers to mental health care among adults with major 
depression and comorbid substance dependence. Psychiatr Serv 64, 863-870. 
Cohen, A.L., Jhung, M.A., Budnitz, D.S., 2006. Stimulant medications and attention 
deficit-hyperactivity disorder. N Engl J Med 354, 2294-2295. 
Compton, W.M., Conway, K.P., Stinson, F.S., Grant, B.F., 2006. Changes in the 
prevalence of major depression and comorbid substance use disorders in the United 
States between 1991-1992 and 2001-2002. Am J Psychiatry 163, 2141-2147. 
111 
 
Conway, K.P., Kane, R.J., Ball, S.A., Poling, J.C., Rounsaville, B.J., 2003. 
Personality, substance of choice, and polysubstance involvement among substance 
dependent patients. Drug Alcohol Depend 71, 65-75. 
Cuffel, B.J., Shumway, M., Chouljian, T.L., MacDonald, T., 1994. A longitudinal 
study of substance use and community violence in schizophrenia. J Nerv Ment Dis 
182, 704-708. 
Drug Enforcement Administration, 2003. ARCOS 2: Report 1, Retail drug 
distribution. Department of Justice: Drug Enforcement Administration. 
Drug Enforcement Administration, 2013. Controlled Substances: Proposed 
Aggregate Production Quotas for 2013. Drug Enforcement Administration, US 
Department of Justice. . 
DeSantis, A.D., Hane, A.C., 2010. "Adderall is definitely not a drug": justifications 
for the illegal use of ADHD stimulants. Subst Use Misuse 45, 31-46. 
Durbin, J., Watson, G.S., 1950. Testing for serial correlation in least squares 
regression. I. Biometrika 37, 409-428. 
Food and Drug Administration. Drug Safety and Risk Management Advisory 
Committee Meeting, February 9 and 10, 2006: table of contents. 
Garfield, C.F., Dorsey, E.R., Zhu, S., Huskamp, H.A., Conti, R., Dusetzina, S.B., 
Higashi, A., Perrin, J.M., Kornfield, R., Alexander, G.C., 2012. Trends in attention 
deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the 
United States, 2000-2010. Acad Pediatr 12, 110-116. 
112 
 
Garnier-Dykstra, L.M., Caldeira, K.M., Vincent, K.B., O'Grady, K.E., Arria, A.M., 
2012. Nonmedical use of prescription stimulants during college: four-year trends in 
exposure opportunity, use, motives, and sources. J Am Coll Health 60, 226-234. 
Garnier, L.M., Arria, A.M., Caldeira, K.M., Vincent, K.B., O'Grady, K.E., Wish, 
E.D., 2010. Sharing and selling of prescription medications in a college student 
sample. J Clin Psychiatry 71, 262-269. 
Goldman, L.S., Genel, M., Bezman, R.J., Slanetz, P.J., 1998. Diagnosis and 
treatment of attention-deficit/hyperactivity disorder in children and adolescents. 
Council on Scientific Affairs, American Medical Association. JAMA 279, 1100-
1107. 
Gould, M.S., Walsh, B.T., Munfakh, J.L., Kleinman, M., Duan, N., Olfson, M., 
Greenhill, L., Cooper, T., 2009. Sudden death and use of stimulant medications in 
youths. Am J Psychiatry 166, 992-1001. 
Grant, B.F., Dawson, D.A., 1998. Age of onset of drug use and its association with 
DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol 
Epidemiologic Survey. Journal of substance abuse 10, 163-173. 
Grant, B.F., Harford, T.C., 1990. Concurrent and simultaneous use of alcohol with 
cocaine: results of national survey. Drug and alcohol dependence 25, 97-104. 
Greenhill, L.L., Pliszka, S., Dulcan, M.K., Bernet, W., Arnold, V., Beitchman, J., 
Benson, R.S., Bukstein, O., Kinlan, J., McClellan, J., Rue, D., Shaw, J.A., Stock, S., 
2002. Practice parameter for the use of stimulant medications in the treatment of 
children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41, 26S-49S. 
113 
 
Grella, C.E., Hser, Y.I., Joshi, V., Rounds-Bryant, J., 2001. Drug treatment outcomes 
for adolescents with comorbid mental and substance use disorders. J Nerv Ment Dis 
189, 384-392. 
Hall, A.J., Logan, J.E., Toblin, R.L., Kaplan, J.A., Kraner, J.C., Bixler, D., Crosby, 
A.E., Paulozzi, L.J., 2008. Patterns of abuse among unintentional pharmaceutical 
overdose fatalities. JAMA : the journal of the American Medical Association 300, 
2613-2620. 
Hall, K.M., Irwin, M.M., Bowman, K.A., Frankenberger, W., Jewett, D.C., 2005. 
Illicit use of prescribed stimulant medication among college students. J Am Coll 
Health 53, 167-174. 
Harris, K.M., Edlund, M.J., 2005. Use of mental health care and substance abuse 
treatment among adults with co-occurring disorders. Psychiatric Services 56, 954-
959. 
Harrison, L.D., Martin, S. S., Enev, T., & Harrington, D., 2007. Comparing drug 
testing and self-report of drug use among youths and young adults in the general 
population. Substance Abuse and Mental Health Services Administration, Office of 
Applied Studies, Rockville, MD. 
Hasin, D.S., Keyes, K.M., Hatzenbuehler, M.L., Aharonovich, E.A., Alderson, D., 
2007a. Alcohol consumption and posttraumatic stress after exposure to terrorism: 
effects of proximity, loss, and psychiatric history. Am J Public Health 97, 2268-
2275. 
Hasin, D.S., Stinson, F.S., Ogburn, E., Grant, B.F., 2007b. Prevalence, correlates, 
disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United 
114 
 
States: results from the National Epidemiologic Survey on Alcohol and Related 
Conditions. Arch Gen Psychiatry 64, 830-842. 
Hedden, S.L., Malcolm, R.J., Latimer, W.W., 2009. Differences between adult non-
drug users versus alcohol, cocaine and concurrent alcohol and cocaine problem users. 
Addict Behav 34, 323-326. 
Herman-Stahl, M.A., Krebs, C.P., Kroutil, L.A., Heller, D.C., 2006. Risk and 
protective factors for nonmedical use of prescription stimulants and 
methamphetamine among adolescents. J Adolesc Health 39, 374-380. 
Herman-Stahl, M.A., Krebs, C.P., Kroutil, L.A., Heller, D.C., 2007. Risk and 
protective factors for methamphetamine use and nonmedical use of prescription 
stimulants among young adults aged 18 to 25. Addict Behav 32, 1003-1015. 
Higashi, A., Zhu, S., Stafford, R.S., Alexander, G.C., 2011. National trends in 
ambulatory asthma treatment, 1997-2009. J Gen Intern Med 26, 1465-1470. 
The White House, Prescription Drug Abuse. 2012.Prescription drug abuse. Office of 
drug Control Policy. Retreived on May 8, 2014 at 
http://www.whitehouse.gov/ondcp/prescription-drug-abuse.accessed. 
US Department of Housing and Urban Development, 2011. The 2010 Annual 
Homeless Assessment Report to Congress. Office of community planning and 
development, Washington, DC. Retreived on May 8, 2014 at 
https://www.onecpd.info/resources/documents/2010homelessassessmentreport.pdf 
Inciardi, J.A., Surratt, H.L., Cicero, T.J., Rosenblum, A., Ahwah, C., Bailey, J.E., 
Dart, R.C., Burke, J.J., 2010. Prescription drugs purchased through the internet: who 
are the end users? Drug and alcohol dependence 110, 21-29. 
115 
 
Johnston, L.D., O’Malley, P. M. & Bachman, J. G., 2003. Monitoring the Future 
National Survey Results on Drug Use, 1975–2002: II. College Students and Adults 
Ages 19–40. National Institute on Drug Abuse: NIH Publication No. 03-
5376.Bethesda, MD.  
Judson, R., Langdon, S.W., 2009. Illicit use of prescription stimulants among college 
students: prescription status, motives, theory of planned behaviour, knowledge and 
self-diagnostic tendencies. Psychol Health Med 14, 97-104. 
Kandel, D.B., Huang, F.Y., Davies, M., 2001. Comorbidity between patterns of 
substance use dependence and psychiatric syndromes. Drug Alcohol Depend 64, 
233-241. 
Kandel, D.B., Logan, J.A., 1984. Patterns of drug use from adolescence to young 
adulthood: I. Periods of risk for initiation, continued use, and discontinuation. 
American journal of public health 74, 660-666. 
Kessler, R.C., Barker, P.R., Colpe, L.J., Epstein, J.F., Gfroerer, J.C., Hiripi, E., 
Howes, M.J., Normand, S.L., Manderscheid, R.W., Walters, E.E., Zaslavsky, A.M., 
2003. Screening for serious mental illness in the general population. Arch Gen 
Psychiatry 60, 184-189. 
Komro, K.A., Toomey, T.L., 2002. Strategies to prevent underage drinking. Alcohol 
Res Health 26, 5-14. 
Kornfield, R., Watson, S., Higashi, A.S., Conti, R.M., Dusetzina, S.B., Garfield, 
C.F., Dorsey, E.R., Huskamp, H.A., Alexander, G.C., 2013. Effects of FDA 




Kosterman, R., Hawkins, J.D., Guo, J., Catalano, R.F., Abbott, R.D., 2000. The 
dynamics of alcohol and marijuana initiation: patterns and predictors of first use in 
adolescence. American journal of public health 90, 360-366. 
Kroutil, L.A., Van Brunt, D.L., Herman-Stahl, M.A., Heller, D.C., Bray, R.M., 
Penne, M.A., 2006. Nonmedical use of prescription stimulants in the United States. 
Drug Alcohol Depend 84, 135-143. 
Kroutil, L.A., Vorburger, M., Aldworth, J., Colliver, J.D., 2010. Estimated drug use 
based on direct questioning and open-ended questions: responses in the 2006 
National Survey on Drug Use and Health. Int J Methods Psychiatr Res 19, 74-87. 
Markowitz, J.S., Straughn, A.B., Patrick, K.S., 2003. Advances in the 
pharmacotherapy of attention-deficit-hyperactivity disorder: focus on 
methylphenidate formulations. Pharmacotherapy 23, 1281-1299. 
Martins, S.S., Mazzotti, G., Chilcoat, H.D., 2006. Recent-onset ecstasy use: 
association with deviant behaviors and psychiatric comorbidity. Exp Clin 
Psychopharmacol 14, 275-286. 
Martins, S.S., Storr, C.L., Zhu, H., Chilcoat, H.D., 2009. Correlates of extramedical 
use of OxyContin versus other analgesic opioids among the US general population. 
Drug Alcohol Depend 99, 58-67. 
McCabe, S.E., 2008. Screening for drug abuse among medical and nonmedical users 
of prescription drugs in a probability sample of college students. Arch Pediatr 
Adolesc Med 162, 225-231. 
McCabe, S.E., Boyd, C.J., 2005. Sources of prescription drugs for illicit use. 
Addictive behaviors 30, 1342-1350. 
117 
 
McCabe, S.E., Boyd, C.J., Couper, M.P., Crawford, S., D'Arcy, H., 2002. Mode 
effects for collecting alcohol and other drug use data: Web and U.S. mail. Journal of 
studies on alcohol 63, 755-761. 
McCabe, S.E., Boyd, C.J., Teter, C.J., 2009. Subtypes of nonmedical prescription 
drug misuse. Drug Alcohol Depend 102, 63-70. 
McCabe, S.E., Boyd, C.J., Young, A., 2007a. Medical and nonmedical use of 
prescription drugs among secondary school students. J Adolesc Health 40, 76-83. 
McCabe, S.E., Cranford, J.A., 2012. Motivational subtypes of nonmedical use of 
prescription medications: results from a national study. The Journal of adolescent 
health : official publication of the Society for Adolescent Medicine 51, 445-452. 
McCabe, S.E., Cranford, J.A., Boyd, C.J., Teter, C.J., 2007b. Motives, diversion and 
routes of administration associated with nonmedical use of prescription opioids. 
Addict Behav 32, 562-575. 
McCabe, S.E., Cranford, J.A., Morales, M., Young, A., 2006a. Simultaneous and 
concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, 
and consequences. J Stud Alcohol 67, 529-537. 
McCabe, S.E., Knight, J.R., Teter, C.J., Wechsler, H., 2005. Non-medical use of 
prescription stimulants among US college students: prevalence and correlates from a 
national survey. Addiction 100, 96-106. 
McCabe, S.E., Teter, C.J., 2007. Drug use related problems among nonmedical users 
of prescription stimulants: a web-based survey of college students from a Midwestern 
university. Drug Alcohol Depend 91, 69-76. 
118 
 
McCabe, S.E., Teter, C.J., Boyd, C.J., 2004. The use, misuse and diversion of 
prescription stimulants among middle and high school students. Subst Use Misuse 
39, 1095-1116. 
McCabe, S.E., Teter, C.J., Boyd, C.J., 2006b. Medical use, illicit use and diversion of 
prescription stimulant medication. J Psychoactive Drugs 38, 43-56. 
McCabe, S.E., West, B.T., Wechsler, H., 2007c. Trends and college-level 
characteristics associated with the non-medical use of prescription drugs among US 
college students from 1993 to 2001. Addiction 102, 455-465. 
Mosholder, A.D., Gelperin, K., Hammad, T.A., Phelan, K., Johann-Liang, R., 2009. 
Hallucinations and other psychotic symptoms associated with the use of attention-
deficit/hyperactivity disorder drugs in children. Pediatrics 123, 611-616. 
Muthén, L.K.a.M., B.O. , 1998-2010. Mplus User's Guide. Sixth Edition. Muthén & 
Muthén, Los Angeles,CA. 
National Institute on Drug Abuse, 2009. DrugFacts: Stimulant ADHD Medications - 
Methylphenidate and Amphetamines. National Institute on Drug Abuse.  
Retrieved at : 
http://www.drugabuse.gov/publications/drugfacts/stimulant-adhd-medications-
methylphenidate-amphetamines 
Nylund, K.L., Asparoutiov, T., Muthen, B.O., 2007. Deciding on the number of 
classes in latent class analysis and growth mixture modeling: A Monte Carlo 
simulation study. Struct Equ Modeling 14, 535-569. 
119 
 
Olfson, M., Gameroff, M.J., Marcus, S.C., Jensen, P.S., 2003. National trends in the 
treatment of attention deficit hyperactivity disorder. Am J Psychiatry 160, 1071-
1077. 
Peters, R.H., Greenbaum, P.E., Edens, J.F., Carter, C.R., Ortiz, M.M., 1998. 
Prevalence of DSM-IV substance abuse and dependence disorders among prison 
inmates. Am J Drug Alcohol Abuse 24, 573-587. 
Pliszka, S.R., McCracken, J.T., Maas, J.W., 1996. Catecholamines in attention-
deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc 
Psychiatry 35, 264-272. 
Poulin, C., 2007. From attention-deficit/hyperactivity disorder to medical stimulant 
use to the diversion of prescribed stimulants to non-medical stimulant use: 
connecting the dots. Addiction 102, 740-751. 
Roe, C.M., McNamara, A.M., Motheral, B.R., 2002. Gender- and age-related 
prescription drug use patterns. The Annals of pharmacotherapy 36, 30-39. 
Safer, D.J., 2000. Are stimulants overprescribed for youths with ADHD? Ann Clin 
Psychiatry 12, 55-62. 
Safer, D.J., Zito, J.M., Fine, E.M., 1996. Increased methylphenidate usage for 
attention deficit disorder in the 1990s. Pediatrics 98, 1084-1088. 
Substance Abuse and Mental Health Services Administration, 2007. Results from the 
2006 National Survey on Drug Use and Health: National Findings. Office of Applied 




Substance Abuse and Mental Health Services Administration, 2008. Results from the 
2007 National Survey on Drug Use and Health: National Findings. Office of Applied  
Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343. Rockville, 
MD. 
Substance Abuse and Mental Health Services Administration, 2009a. The NSDUH 
Report: Nonmedical Use of Adderall®  among Full-Time College Students. Office of 
Applied Studies, Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2009b. Results from 
the 2008 National Survey on Drug Use and Health: National Findings. Office of 
Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434. 
Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2010. Results from the 
2009 National Survey on Drug Use and Health: Volume I. Summary of National 
Findings. Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. 
SMA 10-4856. Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2011. Results from the 
2010 National Survey on Drug Use and Health: Summary of National Findings. 
Office of Applied Studies, NSDUH Series H-41, HHS Publication No. SMA 11-
4658. Rockville, MD.   
Substance Abuse and Mental Health Services Administration, 2012. Results from the 
2011 National Survey on Drug Use and Health: Summary of National Findings. 
Office of Applied Studies, NSDUH Series H-44, HHS Publication No. SMA 12-
4713. Rockville, MD. 
121 
 
Substance Abuse and Mental Health Services Administration, 2011. Drug Abuse 
Warning Network, 2009: Methodology Report. Office of Applied Studies, Substance 
Abuse and Mental Health Services Administration, Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2013a. The DAWN 
Report: Emergency Department Visits Involving Attention Deficit/Hyperactivity 
Disorder Stimulant Medications. Substance Abuse and Mental Health Services 
Administration, Office of Applied Studies, Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2013b. Results from 
the 2012 National Survey on Drug Use and Health: Summary of National Findings. 
Office of Applied Studies, NSDUH Series H-46, HHS Publication No. (SMA) 13-
4795. Rockville, MD. 
Substance Abuse and Mental Health Services Administration, 2009. Treatment 
Episode Data Set (TEDS): 1997-2007. National Admissions to Substance Abuse 
Treatment Services. Office of Applied Studies, DASIS Series: S-45, DHHS 
Publication No. (SMA) 09-4360, Rockville, MD. 
Schepis, T.S., Krishnan-Sarin, S., 2009. Sources of prescriptions for misuse by 
adolescents: differences in sex, ethnicity, and severity of misuse in a population-
based study. J Am Acad Child Adolesc Psychiatry 48, 828-836. 
Schepis, T.S., Marlowe, D.B., Forman, R.F., 2008. The availability and portrayal of 
stimulants over the Internet. J Adolesc Health 42, 458-465. 
Setlik, J., Bond, G.R., Ho, M., 2009. Adolescent prescription ADHD medication 




Sichilima, T., Rieder, M.J., 2009. Adderall and cardiovascular risk: A therapeutic 
dilemma. Paediatr Child Health 14, 193-195. 
Simoni-Wastila, L., 2000. The use of abusable prescription drugs: the role of gender. 
J Womens Health Gend Based Med 9, 289-297. 
StataCorp, 2013. Stata Statistical Software: Release 13. StataCorp LP, College 
Station, TX. 
Strain, E.C., 2002a. Assessment and treatment of comorbid psychiatric disorders in 
opioid-dependent patients. Clin J Pain 18, S14-27. 
Strain, E.C., 2002b. Assessment and treatment of comorbid psychiatric disorders in 
opioid-dependent patients. Clin J Pain 18, S14-27. 
Sweeney, C.T., Sembower, M.A., Ertischek, M.D., Shiffman, S., Schnoll, S.H., 2013. 
Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug 
abuse. J Addict Dis 32, 1-10. 
Teter, C.J., Falone, A.E., Cranford, J.A., Boyd, C.J., McCabe, S.E., 2010. 
Nonmedical use of prescription stimulants and depressed mood among college 
students: frequency and routes of administration. J Subst Abuse Treat 38, 292-298. 
Teter, C.J., McCabe, S.E., Boyd, C.J., Guthrie, S.K., 2003. Illicit methylphenidate 
use in an undergraduate student sample: prevalence and risk factors. 
Pharmacotherapy 23, 609-617. 
Teter, C.J., McCabe, S.E., Cranford, J.A., Boyd, C.J., Guthrie, S.K., 2005. 
Prevalence and motives for illicit use of prescription stimulants in an undergraduate 
student sample. J Am Coll Health 53, 253-262. 
123 
 
Teter, C.J., McCabe, S.E., LaGrange, K., Cranford, J.A., Boyd, C.J., 2006. Illicit use 
of specific prescription stimulants among college students: prevalence, motives, and 
routes of administration. Pharmacotherapy 26, 1501-1510. 
Tittle, C.R., Ward, D.A., Grasmick, H.G., 2003. Self-control and crime/deviance: 
Cognitive vs. behavioral measures. J Quant Criminol 19, 333-365. 
Vetter, V.L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., Webb, C.L., 
2008. Cardiovascular monitoring of children and adolescents with heart disease 
receiving medications for attention deficit/hyperactivity disorder [corrected]: a 
scientific statement from the American Heart Association Council on Cardiovascular 
Disease in the Young Congenital Cardiac Defects Committee and the Council on 
Cardiovascular Nursing. Circulation 117, 2407-2423. 
Visser, S.N., Danielson, M.L., Bitsko, R.H., Holbrook, J.R., Kogan, M.D., 
Ghandour, R.M., Perou, R., Blumberg, S.J., 2014. Trends in the parent-report of 
health care provider-diagnosed and medicated attention-deficit/hyperactivity 
disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 53, 34-46 
e32. 
Volkow, N.D., Fowler, J.S., Wang, G., Ding, Y., Gatley, S.J., 2002. Mechanism of 
action of methylphenidate: insights from PET imaging studies. J Atten Disord 6 
Suppl 1, S31-43. 
Wadley, J.B., S., 2013. American teens more cautious about using synthetic drugs. 
University of Michigan. 
Wang, P.S., Lane, M., Olfson, M., Pincus, H.A., Wells, K.B., Kessler, R.C., 2005. 
Twelve-month use of mental health services in the United States: results from the 
124 
 
National Comorbidity Survey Replication. Archive of General Psychiatry 62, 629-
640. 
Westover, A.N., Halm, E.A., 2012. Do prescription stimulants increase the risk of 
adverse cardiovascular events?: A systematic review. BMC Cardiovasc Disord 12, 
41. 
White, B.P., Becker-Blease, K.A., Grace-Bishop, K., 2006. Stimulant medication 
use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll 
Health 54, 261-268. 
Wilens, T.E., Adler, L.A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., 
Utzinger, L., Fusillo, S., 2008. Misuse and diversion of stimulants prescribed for 
ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 
47, 21-31. 
Zito, J.M., Safer, D.J., DosReis, S., Gardner, J.F., Magder, L., Soeken, K., Boles, M., 
Lynch, F., Riddle, M.A., 2003. Psychotropic practice patterns for youth: a 10-year 
perspective. Arch Pediatr Adolesc Med 157, 17-25. 
Zuvekas, S.H., Vitiello, B., 2012. Stimulant medication use in children: a 12-year 









Lian-Yu Chen, M.D. 
PERSONAL/CONTACT INFORMATION 
 
Johns Hopkins Bloomberg School of Public Health 
Address: 624 North Broadway. 7th floor, suite 784  
Baltimore MD 21205 
Email: liachen@jhsph.edu 
Phone number: (410)336-7466 
 
EDUCATION & TRAINING 
Period Degree/Program Institution Field of 
Study 
2010 – 2014 Ph.D. Department of Mental 
Health, Johns Hopkins 






2009 - 2010 Chief Resident Taipei City Psychiatric 
Center, Taiwan 
Psychiatry 
2006 - 2010 Residency Taipei City Psychiatric 
Center, Taiwan 
Psychiatry 
1998-2006 M.D.  National Cheng-Kung 
University, Taiwan 
Medicine 




  LICENSURE AND BOARD CERTIFICATION 
Advanced Cardiovascular Life Support License, Taiwan, 2014  
National Board of Psychiatric Medicine, Taiwan, 2010 
Medical License, Taiwan, 2006 
 
AWARDS & HONORS 
Lucy Shum Award, Johns Hopkins Bloomberg School of Public Health, 2014 
Sommer Scholarship, Johns Hopkins Bloomberg School of Public Health, 2012-  
NIDA Women & Sex/Gender Junior Investigator Travel Award for meeting of the  
College on Problems of Drug Dependence (CPDD), 2012  
Government Scholarship to Study Abroad, Ministry of Education, Taiwan, 2009  
Clinical Excellence Award, Taipei City Psychiatric Center, Taiwan, 2008  
Scholarship for Exchange Clerkship in Duke University Medical Center, 2004  






Chen LY, Alexandre PK & Martins SS. Correlates of nonmedical use of Adderall®  
in the United States. Oral presentation at 73rd annual meeting at College Problem on 
Drug Dependence. Hollywood, Florida. June 21st, 2011. 
Poster Presentation 
Chen LY, Crum RM, Strain EC, Kaufmann CN, Alexander GC, & Mojtabai R. 
Patterns of concurrent substance use among prescription stimulant misusers: Results 
from the National Survey on Drug Use and Health (NSDUH). Poster to be presented 
presentation at 76th annual meeting of College Problem on Drug Dependence 
on June 17, 2014 
Chen LY, Kaufmann CN, Alexander GC, Mojtabai R, Martins SS. Correlates of  
nonmedical use of ADHD stimulants versus nonmedical use of other stimulants in a 
U.S.  
national sample. Poster presentation at 29th International Conference on  
Pharmacopidemiology and Therapeutic Risk Management, Montréal Convention 
Center,  
Montréal, Canada. August 28, 2013. 
Kaufmann CN, Chen LY, Spira AP, Canham SL, Alexander GC, Mojtabai R. Trends 
in  
the use of non-benzodiazepine sleep-aid medications in the United States, 1996-
2010.  
Poster presentation at 29th International Conference on Pharmacopidemiology and  
Therapeutic Risk Management, Montréal Convention Center, Montréal, Canada. 
August  
28, 2013. 
Kaufmann CN, Chen LY, Crum RM, Mojtabai R. Treatment Seeking and Barriers to  
Treatment for Alcohol Use in Persons with Alcohol Use Disorders and Comorbid 
Mood  
or Anxiety Disorders. Poster presentation at 75 the annual meeting at College 
Problem on  
Drug Dependence. San Diego, California. June 16, 2013. 
Kaufmann, CN, Mojtabai R, Hock RS, Thorpe R, Canham SL, Chen LY, Spira AP.  
Racial/ethnic differences in trajectories of insomnia Severity among older adults: 
Results  
from the Health and Retirement Study. Poster presented at SLEEP 2013 Meeting, 
Baltimore, Maryland. June 5, 2013. 
Chen LY, Crum RM, Martins SS, Mojtabai R & Strain EC. Gender differences in  
substance use and mental health service utilization among persons with substance use  
disorders with vs. without comorbid major depression.  Poster presentation at 74 
the annual meeting at College Problem on Drug Dependence. Palm Spring, 
California. June 12, 2012.  
Chen LY, Crum RM, Martins SS & Mojtabai R. Service use and barriers to mental  
health care in major depression and comorbid substance use disorders. Poster  
presentation at the 165 the Annual Meeting of American Psychiatric Association.  
Philadelphia, PA, May 9, 2012. 
127 
 
Martins SS, Chen LY, Fenton M, Keyes KM & Storr CL. Nonmedical prescription 
opioid use and use disorders secondary to nonmedical use among U.S. young adults by 
educational attainment.  Poster to be presented at the 50th annual meeting at American 
College of Neuropsychopharmacology. Hawaii, Dec 2012. 
Chen LY & Huang MC. Disulfiram induced hypersensitivity----a case report. Poster 
presentation at the 47th Annual Meeting of Taiwanese Society of Psychiatry. Taiwan. 
2008. 
Chen LY & Huang MC. Remarkable urinary tract symptoms associated with chronic 
ketamine abuse: two cases reports. Poster presentation at the 47th Annual Meeting of 
Taiwanese Society of Psychiatry. Taiwan. 2008 
Chen LY & Lin SK. Ziprasidone augmentation in the treatment of refractory 
obsessive-compulsive disorder and schizophrenia: A case Report. Poster presentation 
at the 46th Annual Meeting of Taiwanese Society of Psychiatry.Taiwan. 2007.  
Chen LY & Lin SK. Empirical experiences of rivastigmine in the treatment of 
benzodiazepines tolerance: Two cases reports. Poster presentation at the 46th Annual 
Meeting of Taiwanese Society of Psychiatry. Taiwan. 2007.  
 
PUBLICATIONS  
Chen LY, Crum RM, Strain EC, Kaufmann CN, Alexander GC, & Mojtabai R. 
National Variation of ADHD Medication treatment and nonmedical ADHD 
medication use. In preparation.  
Chen LY, Strain EC, Crum RM, Storr C, & Mojtabai R. Sources of  Nonmedically 
Used Prescription Stimulants: Differences in Recency and Severity of Misuse in a 
Population-Based Study. Under review. 
Chen LY, Crum RM, Strain EC, Kaufmann CN, Alexander GC, & Mojtabai R. 
Prescriptions, nonmedical use, and ER visits of prescription stimulants. Under 
review. 
Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, & Mojtabai R. Patterns 
of concurrent substance use among nonmedical ADHD stimulant users: Results from 
the National Survey on Drug Use and Health. In press, Drug and Alcohol Depend. 
2014 June. 
Martins SS, Levin D, Chen LY, Keyes KM, Magdalena Cerdá M, Storr CL. 
Nonmedical Prescription Opioid Use and Use Disorders secondary to Nonmedical 
Use among U.S. Young Adults by Educational Attainment. Under review.  
Eaton WW, Chen LY, Dohan FC,  Kelly DL, Cascella N.A Case Study of 
Schizophrenia and Immune Reaction to Gluten. Under review. 
Chen LY, Strain EC, Alexandre PK, Alexander GC, Mojtabai R, Martins SS. 
Correlates  
of nonmedical use of stimulants and methamphetamine use in a national sample. 
Addict Behav. 2014 Feb 12;39(5):829-836.  
Chen LY, Strain EC, Crum RM, & Mojtabai R. Gender differences in substance 
abuse  
treatment and barriers to care among persons with substance use disorders with and  
without comorbid major depression. J Addict Med. 2013 Sep-Oct;7(5):325-34.  
128 
 
Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, & Mojtabai R. Service 
use  
and barriers to mental health care in major depression and comorbid substance use  
disorders. Psychiatr Serv. 2013 Sep 1;64(9):863-70.  
Kaufmann CN, Chen LY, Crum RM, Mojtabai R. Treatment seeking and barriers to  
treatment for alcohol use in persons with alcohol use disorders and comorbid mood 
or  
anxiety disorders. Soc Psychiatry Psychiatr Epidemiol. 2013 Jul 31. [Epub ahead of 
print].  
Mojtabai R, Chen LY, Kaufmann CN, Crum RM. Comparing barriers to mental 
health  
treatment for alcohol use in persons with alcohol use disorders and comorbid mood 
or  
anxiety disorders. J Subst Abuse Treat. 2014 Feb;46(2):268-73. 
Chen LY, Chen KP, Huang MC. Cystitis associated with chronic ketamine abuse.  
Psychiatry Clin Neurosci. 2009 Aug ; 63(4):591.  
Chen LY, LI Hor. Determination of the role of cytotoxicity in Vibrio vulnificus 
virulence in mice by characterizing of a noncytotoxic mutant. A medical thesis. 2004. 
 
EDITORIAL ACTIVITIES  
Peer Review Activities  
Addictive behaviors - 2013 - present  




Prescription stimulants: temporal trends, geographical variations, and heterogeneity 
of the nonmedical users, 2013-2014. 
Correlates of nonmedical use of stimulants and methamphetamine use in a national  
sample, 2012-2013.  
Gender differences in substance use and mental health service utilization among 
persons  
with substance use disorders with vs. without comorbid major depression, 2011-
2012.  
Service use and barriers to mental health care in major depression and comorbid 
substance use disorders, 2011-2012.  
Correlates of illegal drugs use and nonmedical use of Adderall®  in the United States,  
2010-2011.  
Factors associated with MMT retention in Northern Taiwan among heroin users 
enrolled  
in methadone treatment in northern Taiwan, 2010-2011.  
The urology and CNS consequences post ketamine dependence, 2008- 2009. 
 
TEACHING ACTIVITIES  
129 
 
“Perspective of Psychiatry: The public health framework”, 2012/ August-November, 
Johns Hopkins Bloomberg School of Public Health 
Instructor: Paul R McHugh, MD, Professor  
                   Alan J Romanoski, MD, MPH, Associate Professor 
Teaching assistant: Lian-Yu Chen 
 
“Introduction to mental health service”, 2014/ March-May, Johns Hopkins 
Bloomberg School of Public Health 
Instructor: Ramin Mojtabai, MD, Associate Professor  
Teaching assistant: Lian-Yu Chen 
 
PROFESSIONAL SOCIETIES  
Center Affiliates of Center for drug and safety in Johns Hopkins Bloomberg School 
of Public Health, 2012-date  
Taiwanese Society of Addiction Science, member, 2008- date  
Center for Development of Psychotherapy, member, Taiwan, 2007- date  
Taiwanese Society of Psychiatry, member, 2006- date 
 
SCIENTIFIC MEETINGS  
29th International Society for Pharmacoepidemiology, Montreal, Canada, 2013  
74th annual meeting at College Problem on Drug Dependence, California, USA, 
2012  
165th annual meeting at American Psychiatric Association, Philadelphia, USA, 2012  
73rd annual meeting at College Problem on Drug Dependence, Florida, USA, 2011  
2nd World Congress of Asian Psychiatry, Taipei, Taiwan, 2010  
49th Annual Meeting of Taiwanese Society of Psychiatry, Taipei, Taiwan, 2010  
48th Annual Meeting of Taiwanese Society of Psychiatry, Tainan, Taiwan, 2009  
47th Annual Meeting of Taiwanese Society of Psychiatry, Taipei, Taiwan, 2008  
46th Annual Meeting of Taiwanese Society of Psychiatry, Kaohsiung, Taiwan, 2007 
 
LEARDERSHIP EXPERIENCES 
Behavioral Health International Group (BHIG) in JHSPH, member, 2010- date. 
2nd World Congress of Asian Psychiatry, Host. Taipei, Taiwan, 2010  
Anti-AIDS Condom Delivery Street Campaign, Host and organizer. Taiwan, 2003. 
National delegate in General Assembly of International Federation of Medical 
Student Association (IFMSA). Former Yugoslavia, 2003. 
Federation of Medical Student Association in Taiwan (IFMSA) Standing Committee 
on Reproductive Health & AIDS (SCORA), National local officer, 2002-2003. 
National delegate in East Asian Medical Students' Conference, Taiwan, 2002. 
Speech and Debate Club of National Chung Kung University, president, Taiwan, 
2001-2002. 






Languages: Fluent in Taiwanese, Mandarin Chinese and English  
Technical: Stata, Microsoft Office, Mplus, GIS 
